Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
03/2009 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions March listing by industry category 03/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
03/26/2009 > patent applications in patent subcategories. listing by industry category

20090082253 - Antibacterial agent based on fatty acid esters of hydroxy carboxylic acid acids: P

20090082252 - Compositions containing peptides with non-natural amino acids and methods of use: The invention relates generally to peptides comprising one or more non-natural amino acids residues and their use in cosmetic and personal care compositions.... Agent: Avon Products, Inc.

20090082250 - Control of gene expression using a complex of an oligonucleotide and a regulatory peptide: A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an... Agent: Nikolai & Mersereau, P.A.

20090082254 - Coupling of polypeptides at the c-terminus: The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090082251 - Mitochondrial dna variants associated with metabolic syndrome: Provided are methods of identifying Metabolic Syndrome phenotypes for an organism or a biological sample derived therefrom which methods are based on detecting a polymorphism, haplotype, haplotype group, or haplotype subgroup in the mitochondrial genome of the organism and correlating the polymorphism or haplotype to a Metabolic Syndrome phenotype. Also... Agent: Quine Intellectual Property Law Group, P.C.

20090082249 - Nutritional supplement for a category of hiv patients: The present invention relates to a nutritional product for HIV patients that are not on Highly Active Antiretroviral Therapy. More specifically the invention relates to a nutritional composition comprising oligosaccharides. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.... Agent: Foley And Lardner LLP Suite 500

20090082255 - Acidic insulin preparations having improved stability: The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090082256 - Concomitant pharmaceutical agents and use thereof: (b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet... Agent: Leydig Voit & Mayer, Ltd

20090082257 - Malpeg-hb conjugate- containing compositions for delivering carbon monoxide (co) to cells: The present invention relates to compositions for delivering carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver CO to cells.... Agent: Gordon & Rees LLP

20090082259 - Deuterium-enriched octreotide: The present application describes deuterium-enriched octreotide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082258 - Means and methods for treating advanced stage neuroblastoma: The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases.... Agent: Birch Stewart Kolasch & Birch

20090082260 - Combination of an immunosuppressant and a ppar gamma agonist for the treatment of an undesirable immune response: A method for the treatment or prevention of an undesirable immune response, comprising the simultaneous administration of an immunosuppressant such as cyclosporine and a PPAR-gamma agonist, such as pioglitazone or rosiglitazone. Undesirable immune responses include, for example, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, or transplant rejection.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090082261 - Urea-containing peptides as inhibitors of viral replication: The variables T, R1-R9, J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical... Agent: Cantor Colburn, LLP

20090082264 - 123 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090082272 - Active peptide of bone morphogenetic protein-2, method for manufacturing the same and the application: A bone morphogenetic protein-2 active peptide is characterized in that the structure is S[PO4]KIPKASSVPTELSAISTLYLDDD or CCCCDDDS[PO4]KIPKASSVPTELSAISTLYL or C16H31O—NH—CCCCGGGS[PO4]-KIPKASSVPTELSAISTLYL. It overcomes the disadvantages of existing BMP-2, such as short half life, difficulty of sustained effect, complexity of equipments and preparation techniques, long production cycle, low yield, expensive price, and is accordingly... Agent: Matthias Scholl

20090082269 - Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same: It is intended to provide a drug for ameliorating symptoms or diseases caused by heavy metals (for example, Wilson's disease, heavy metal toxication, aging, fulminant hepatitis and so on) which has a high safety without any fear of side effect, can eliminate heavy metals such as copper ion accumulated in... Agent: Osha Liang L.L.P.

20090082271 - Agents that reduce apoe-induced impairment of mitochondria and methods of use thereof: The present invention provides isolated cells comprising a nucleic acid encoding a toxic form of apoE. The present invention further provides screening methods for identifying compounds that reduce apoE-induced impairment of mitochondrial integrity and/or function. The present invention further provides kits for use in carrying out a subject screening method.... Agent: Bozicevic, Field & Francis LLP

20090082274 - Collections of repeat proteins comprising repeat modules: The present invention relates to collections of repeat proteins comprising repeat modules which are derived from one or more repeat units of a family of naturally occurring repeat proteins, to collections of nucleic acid molecules encoding said repeat proteins, to methods for the construction and application of such collections and... Agent: Arent Fox LLP

20090082265 - Compositions and methods for treating diseases: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090082266 - Conjugate of water-soluble hyaluronic acid modification product with glp-a analogue: The present invention provides a conjugate obtained by binding, to a GLP-1 analogue into which a mercapto group is incorporated, water soluble hyaluronic acid modification product obtained by incorporating a substituent via an amide bond to the carboxyl group of glucuronic acid portion of hyaluronic acid as a derivative thereof,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090082263 - Drug and method for improving brain function: It is intended to provide a novel remedy for improving the brain function or preventing the same from worsening and a novel administration method for the remedy. Namely, a composition for preventing the brain function from worsening or improving the brain function which contains a cell growth factor. It is... Agent: Ropes & Gray LLP

20090082273 - Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the protease peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the protease peptides, and methods of identifying... Agent: Celera Corporation

20090082268 - Muteins of placental growth factor type i, preparation method and application thereof: The present invention relates to chemically stable muteins of type 1 Placental Growth Factor (PLGF-1) bearing the substitution or elimination of a cysteine residue from the wild type protein amino acid sequence, their preparation, their therapeutic and cosmetic uses, and pharmaceutical and cosmetic compositions containing said derivatives. The invention likewise... Agent: Beusse Wolter Sanks Mora & Maire, P. A.

20090082275 - Ob protein compositions and methods: The present invention provides methods and compositions for, for example, effecting weight loss and treating excess weight by administering OB protein, or a derivative thereof, in a form for constant supply, for example, continuous administration, at a dosage of less than or equal to about 1 mg protein/kg body weight/day.... Agent: Amylin Pharmaceuticals, Inc.

20090082267 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Lowrie, Lando & Anastasi, LLP

20090082262 - Processed human chemokines phc-1 and phc-2: The present invention is related to newly identified compounds, polynucleotide sequences encoding the amino acid sequences of the compounds, as well as agonists, antagonists or inhibitors of the compounds for chemokine receptors, especially the CCR-5 receptor and their use in the field of diagnostics and therapeutics involving the chemokine receptors.... Agent: Dardi & Associates, PLLC

20090082276 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20090082270 - Uses of cerberus, coco and derivatives thereof: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.... Agent: Ropes & Gray LLP

20090082277 - Potentiation of anticancer agents: The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer.... Agent: Clark & Elbing LLP

20090082278 - Use of compounds inducing the synthesis of sirt proteins in or for the preparation of a cosmetic or pharmaceutical composition: A cosmetic dermo-pharmaceutical, or dermatological composition having as an active agent in an acceptable cosmetic or pharmaceutical medium, at least one compound able to activate the synthesis or SIRT proteins in skin cells.... Agent: Young & Thompson

20090082279 - Peptide antagonists of zonulin and methods for use of the same: Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20090082280 - Plant-derived elastin binding protein ligands and methods of using the same: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing... Agent: Pepper Hamilton LLP

20090082281 - Compositions and methods for counteracting effects of reactive oxygen species and free radicals: Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by... Agent: Wolf Greenfield & Sacks, P.C.

20090082282 - Use of pde iii inhibitors for the reduction of heart size in mammals suffering from heart failure: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090082283 - Dipeptides for prevention of muscle breakdown and microbial infection: The subject invention provides dipeptides useful in promoting healthy muscle tissues as well as effective immune responses. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090082284 - Oil-in-water emulsions and cosmetic compositions containing the emulsions: Oil-in-water emulsions of at least one non-ionic emulsifier; at least one anionic co-emulsifier; an oil component having a polarity of at least 20 mN/m or a mixture of oil components wherein at least 75 weight-% of the oils constituting the mixture have a polarity of at least 20 mN/m; 6... Agent: Fox Rothschild LLP

20090082285 - Adiponectin expression promoter: To prevent or alleviate various pathologies caused by lifestyle-related diseases, etc., the present invention provides a substance having an effect of promoting the expression and elevating the expression level of adiponectin, and applications thereof. An adiponectin expression promoting agent containing, as an active ingredient, at least one cyanidin compound selected... Agent: Kratz, Quintos & Hanson, LLP

20090082286 - Method for the production of resveratrol in a recombinant oleaginous microorganism: Methods to produce resveratrol and/or resveratrol glucoside in a recombinant oleaginous microorganism are provided. Expression of a resveratrol synthase gene in combination with genes involved in the phenylpropanoid pathway enabled recombinant microbial production of resveratrol in significant amounts.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090082287 - Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes: The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090082289 - Adenoviral vectors having a protein ix deletion: Thus, for example, the adenoviral vector of this invention- can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used... Agent: Townsend And Townsend And Crew, LLP

20090082292 - Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells and methods of treating ophthalmic and dermatological diseases: A pharmaceutical composition blocks angiogenesis and contains as an active agent at least one nucleotide sequence from nucleic acid molecule SEQ ID NO. 3, fragments thereof containing at least twelve contiguous nucleotides and derivatives thereof; and nucleic acid sequences containing at least twelve contiguous nucleotides of the nucleic acid molecule... Agent: Ip Group Of Dla Piper US LLP

20090082299 - Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells: The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence comprising a codon optimized IL-15 sequence. The present invention further provides expression... Agent: Townsend And Townsend And Crew, LLP

20090082295 - Combinations and methods of using an immunomodulatory oligodeoxynucleotide: The present invention relates to combination therapies for the treatment of cancer. The combination of agents include oligonucleotides and one or more chemotherapeutic agents.... Agent: Scully, Scott, Murphy & Presser, P.C.

20090082297 - Compositions and methods for regulating gene expression: Methods, compositions and kits for selectively increasing the expression of a target gene are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090082294 - Diagnosis, prevention and treatment of cancer: Nucleic acid molecules useful in the treatment of cancer are provided. The nucleic acid molecules may include a short interfering ribonucleic acid molecule directed against fer mRNA. A kit for the treatment of cancer including a short interfering ribonucleic acid molecule of the presently described subject matter, as well as... Agent: The Nath Law Group

20090082303 - Drug for preventing and treating atherosclerosis: The present invention relates to a prophylactic/therapeutic agent for atherosclerosis comprising GM3 synthase inhibitor or inhibitor for expression of GM3 synthase gene, a diagnostic product for atherosclerosis comprising antibody to GM3 synthase, a method of diagnosis for atherosclerosis using antibody to GM3 synthase and others, an use of GM3 or... Agent: Foley And Lardner LLP Suite 500

20090082301 - Gene therapy for renal failure: The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in dogs and cats, by administration of the recombinant... Agent: Judy Jarecki-black Ph.d., J.d.

20090082290 - Intra-vascular kidney gene therapy with plasmid encoding bmp-7: The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of both acute and chronic renal failure in mammals, advantageously in humans, dogs and cats, by intra-vascular kidney administration... Agent: Judy Jarecki-black, Ph.d,j.d

20090082288 - Methods and compositions for the treatment of uveitis: Pharmaceutical compositions are disclosed that are of use for the treatment of uveitis. These compositions include a suppressive oligonucleotide. These compositions including an immunosuppressive oligonucleotide can be used for the treatment of uveitis, including anterior, posterior, and diffuse uveitis.... Agent: Klarquist Sparkman, LLP

20090082298 - Methods for producing micrornas: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible... Agent: Wilmerhale/new York

20090082291 - Methods of treatment of acute renal failure: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a... Agent: Cooper & Dunham, LLP

20090082302 - Modulation of eif4e-bp2 expression: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.... Agent: Mcdermott Will & Emery

20090082300 - Modulation of transthyretin expression: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090082296 - Mycobacterial antigens expressed during latency: A method is provided for identifying mycobacterial genes that are induced or up-regulated under culture conditions that are nutrient-starving and which maintain mycobacterial latency, said conditions being obtainable by batch fermentation of a mycobacterium for at least 20 days post-inoculation, when compared with culture conditions that are not nutrient-starving and... Agent: Evan Law Group LLC

20090082293 - Techniques and compositions for treating cardiovascular disease by in vivo gene delivery: Methods are provided for treating patients with cardiovascular disease, including heart disease and peripheral vascular disease. The preferred methods of the present invention involve in vivo delivery of genes, encoding angiogenic proteins or peptides, to the myocardium or to peripheral ischemic tissue, by introduction of a vector containing the gene... Agent: Morrison & Foerster LLP

20090082304 - Methods of treating hematological malignancies with nucleoside analog drugs: The present invention provides methods of treating hematological malignancies, including multi-drug resistant malignancies, with 8-amino-adenosine and variants thereof. Also encompassed by the present invention is a method of predicting the response of a patient diagnosed with a hematological malignancy to treatment with a nucleoside analog and a method of screening... Agent: Oppenheimer Wolff & Donnelly LLP

20090082305 - Method of improving storage stability of substance: The present invention relates to a method of improving storage stability of reduced form of nicotinamide adenine dinucleotide, reduced form of nicotinamide adenine dinucleotide phosphate, or a salt thereof, or ascorbic acid, an ascorbic acid derivative, or a salt thereof, which comprises allowing the substance to coexist with an L-arginine... Agent: Fitzpatrick Cella Harper & Scinto

20090082306 - Deuterium-enriched telbivudine: The present application describes deuterium-enriched telbivudine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082307 - Method for producing oligopolysaccharides: The invention concerns the production by microbiological process of oligopolysaccharides of biological interest. More particularly, the invention concerns a method for synthesizing in vivo the oligopolysaccharides by internalization of an exogenous precursor in growing bacterial cells expressing adequate modifying and glycosylating genes.... Agent: Foley And Lardner LLP Suite 500

20090082308 - Benzothiophene derivatives: The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells,... Agent: Merck And Co., Inc

20090082309 - Method of regulating glucose metabolism, and reagents related thereto: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090082310 - Prodrugs of thyroid hormone analogs: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090082311 - 2-aminobutanol compound and use thereof for medical purposes: wherein R1 is a hydrogen atom or P(═O) (OH)2, R2 is an alkyl having 1 to 4 carbon atoms optionally substituted by hydroxyl group(s) or optionally substituted by halogen atom(s), R3 is a hydrogen atom; a halogen atom; cyano; an alkyl having 1 to 4 carbon atoms optionally substituted by... Agent: Birch Stewart Kolasch & Birch

20090082312 - Deuterium-enriched zoledronic acid: The present application describes deuterium-enriched zoledronic acid, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082313 - Multikinase inhibitors for use in the treatment of cancer: e

20090082314 - Targeting prodrugs for the treatment of gastrointestinal diseases: Provided herein are compounds, compositions and methods for decreasing NFκB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).... Agent: Foley & Lardner LLP

20090082315 - Compositions and methods for controlling cholesterol levels: New compositions and methods are provided for controlling cholesterol levels. The present compositions are uniquely structured to allow a subject to whom the compositions, in the form of unit dosage forms, are administered to benefit from both a statin, such as atorvastatin, and niacin.... Agent: Stout, Uxa, Buyan & Mullins LLP

20090082316 - Composition and method of stabilized sensitive ingredient: The present invention comprises a method of achieving ingredient stabilization in a composition comprising the steps of: combining a pregelatinized starch with at least one sensitive ingredient; adsorbing said sensitive ingredient onto the pregelatinized starch; and wherein said sensitive ingredient is evenly distributed throughout said pregelatinized starch.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090082317 - Low-calcemic 16,23-diene 25-oxime analogs of 1alpha,25-dihydroxy vitamin d3: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy... Agent: Marshall, Gerstein & Borun LLP

20090082318 - Deuterium-enriched mometasone: The present application describes deuterium-enriched mometasone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082319 - Deuterium-enriched budesonide: The present application describes deuterium-enriched budesonide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082320 - Fluorinated 4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.... Agent: Merck And Co., Inc

20090082321 - Steroid containing drug delivery systems: Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.... Agent: Allergan, Inc.

20090082323 - Deuterium-enriched fulvestrant: The present application describes deuterium-enriched fulvestrant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082322 - Gender differences in experimental aortic aneurysm formation: The present invention generally relates to the relevance of gender differences on abdominal aortic aneurysm (AAA) formation and to methods of inhibiting, preventing, and/or treating AAA formation by administering estrogen, and estrogen derivative, and/or estrogen receptor agonist, to an organism in need thereof.... Agent: Marshall, Gerstein & Borun LLP

20090082324 - Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to... Agent: Mallinckrodt Inc.

20090082325 - Cefidinir oral suspension: The present invention discloses a novel powder for oral suspension of cefdinir. Also disclosed are methods of preparing the suspension and methods of treatment using the suspension.... Agent: Paul D. Yasger Abbott Laboratories

20090082326 - Soluble dosage forms containing cephem derivatives suitable for parenteral administration: The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090082327 - Deuterium-enriched meropenem: The present application describes deuterium-enriched meropenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082328 - Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity: This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.... Agent: Edwards Angell Palmer & Dodge LLP

20090082330 - Certain substituted amides, method of making, and method of use thereof: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity... Agent: Millen, White, Zelano & Branigan, P.C.

20090082329 - Novel sulphur-containing cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors: m

20090082331 - S1p receptor modulating compounds and use thereof: The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including... Agent: Jones Day

20090082332 - Purine derivatives for the treatment of viral or allergic diseases and cancers: e

20090082333 - Remedy for xanthoma: A preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt.... Agent: Edwards Angell Palmer & Dodge LLP

20090082334 - Deuterium-enriched quetiapine: The present application describes deuterium-enriched quetiapine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082335 - Deuterium-enriched oxcarbazepine: The present application describes deuterium-enriched oxcarbazepine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082336 - Mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090082337 - Compositions comprising quinolone and methods for treating or controlling infections: Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher... Agent: Bausch & Lomb Incorporated

20090082340 - 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase i: as inhibitors of human casein kinase Iε, and methods of using said compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II)... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090082339 - Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments: The invention relates to azacyclyl-substituted arylthienopyrimidinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the azacyclyl-substituted arylthienopyrimidinones of the invention and their derivatives as MCH antagonists.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090082338 - Preventive or remedy for glaucoma: There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an α1 blocker in combination.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090082341 - 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder: Provided are methods of treating post-traumatic stress disorder with 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide. Also provided are methods of improving resilience with 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide. Also provided are methods of diagnosing post-traumatic stress disorder in a patient.... Agent: Fenwick & West LLP

20090082342 - N-substituted piperidine derivatives as serotonin receptor agents: Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods... Agent: Knobbe Martens Olson & Bear LLP

20090082343 - 1,3-benzothiazinone derivatives and use thereof: n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating... Agent: Edwards Angell Palmer & Dodge LLP

20090082344 - Methods and systems for treating disease: Methods and systems described herein are applicable to the identification of pathogens, pathogenic variants and applicable treatments or remedies. In some embodiments, the pathogen or pathogens bears a causal relationship to a disease state.... Agent: Searete LLC Clarence T. Tegreene

20090082345 - Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors: The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer... Agent:

20090082347 - Pyrrolo[3,2-d]pyrimidines that are selective antagonists of a2b adenosine receptors: e

20090082346 - Substituted pyrrolo-pyrazole derivatives as kinase inhibitors: Compounds represented by formula (Ia) or (Ib) and wherein R and R1 are as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.... Agent: Scully Scott Murphy & Presser, PC

20090082348 - Indazole derivatives: R2 represents a hydrogen atom, CONR2aR2b (wherein R2a and R2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R2a and R2b are combined together with... Agent: Fitzpatrick Cella Harper & Scinto

20090082349 - Thiazolones for use as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090082350 - Soluble epoxide hydrolase inhibitors: Disclosed are heterocylic or heteroaryl compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory,... Agent: Foley & Lardner LLP

20090082352 - Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halo(lower alkyl) group, cyano group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7, R8, R9 and R10 represent hydrogen atom, a halogen atom,... Agent: Greenblum & Bernstein, P.L.C

20090082351 - Pesticide pyrimidinyloxy substituted phenylamidine derivatives: The present invention relates to 2,5-disubstituted-4-pyrimidinyl-substituted-phenyl-amidine derivatives of formula (I) in which the substituents are as in the description, notably to 2,5-dialkyl-4-pyrimidinyl-substituted-phenyl-amidine derivatives, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090082353 - Treatment of epilepsy with non-imidazole alkylamines histamine h3-receptor ligands: The present invention provides new method of treatment of epilepsy with non-imidazole alkylamine derivatives that constitute antagonists of the H3-receptors of histamine.... Agent: Stites & Harbison PLLC

20090082354 - Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof: e

20090082355 - Method of combating root weevils: A method of combating root weevils comprising contacting the root weevils or their food supply, habitat, breeding grounds or their locus with a pesticidally effective amount of a compound of the formula (I) wherein W is Cl or CF3; X and Y are each independently Cl or Br; R1 is... Agent: Brinks, Hofer, Gilson & Lione

20090082357 - Prolyl hydroxylase inhibitors: m

20090082356 - Pyrazine derivatives and use as p13k inhibitors: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090082358 - Vanilloid receptor ligands and their use in treatments: Bicyclic 3,4-fused piperidine compounds, and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints... Agent: Amgen Inc.

20090082359 - 5-pyridinone substituted indazoles: c

20090082361 - Deuterium-enriched imatinib: The present application describes deuterium-enriched imatinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082360 - Use of tyrosine kinase inhibitors for treating cns disorders: The present invention relates to a method for treating CNS disorders, more particularly selected from the group consisting of depression, schizophrenia, anxiety, migraine, memory loss, pain and neurodegenerative diseases, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be... Agent: Sughrue Mion, PLLC

20090082362 - Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure: Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are... Agent: Seth Fidel Neurogen Corporation,

20090082363 - Deuterium-enriched posaconazole: The present application describes deuterium-enriched posaconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082364 - Deuterium-enriched levocedtirizine: The present application describes deuterium-enriched levocetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082366 - Deuterium-enriched telaprevir: The present application describes deuterium-enriched telaprevir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082367 - Triazole derivative or a salt thereof: [Means for Solution] It was found that a triazole derivative or a pharmaceutically acceptable salt thereof, in which the 3-position of triazole ring is substituted with a trisubstituted methyl group and the 5-position is substituted with a lower alkyl, cycloalkyl or the like, has a strong 11β-HSD1-inhibitory activity. In addition,... Agent: Sughrue-265550

20090082365 - Trisubstituted quinazolinone derivatives as vanilloid antagonists: e

20090082368 - Methods of modulating neurotrophin-mediated activity: Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090082370 - Pharmaceutical combinations of pk inhibitors and other active agents: The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R1, Q1, Q2, E, G, T, R4, J1 and J2 are as... Agent: Heslin Rothenberg Farley & Mesiti PC

20090082369 - Pyrrolo[2,3d]pyrimidine compositions and their use: wherein R1 and R2 together form a substituted or unsubstituted heterocyclic ring; R3 is a substituted or unsubstituted aryl moiety; R4 is a hydrogen atom, an unsubstituted alkyl, or a substituted or unsubstituted aryl moiety; and R5 and R6 are each independently a halogen atom, a hydrogen atom or a... Agent: Cooper & Dunham, LLP

20090082372 - Arylmethylene substituted n-acyl-beta-amino alcohols: e

20090082371 - Treatment of viral disease and cancer with nf-kappab inhibitors: A method using quinazoline derivatives, celastrol, cape, BAY 11-7082, rocaglamide, and 7-Methoxy-5,11,12-trihydroxy-coumestan is administered to a mammal for the treatment and prevention of viral diseases and cancers. The chemical compounds are targeted to inhibit NF-κB transcriptional activity. These treatments for viral diseases, especially for infection caused by HIV, and cancers... Agent: Robert E. Bushnell & Law Firm

20090082374 - Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting... Agent: Buchanan Ingersoll & Rooney PC

20090082373 - Uses of 2-[piperidinyl]methyl-2, 3-dihydroimidazo[1,2-c]quinazolin-5(6h)-one for providing an analgesic effect, anti-allergic effect and histamine h1 receptor antagonism effect: The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H1 receptor antagonism effect in a patient to treat a disease or disorder, such as allergy.... Agent: Bacon & Thomas, PLLC

20090082375 - Solid forms comprising 3-(2,5-dimethyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same: Provided herein are solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.... Agent: Jones Day

20090082378 - Derivatives of 4-(2-amino-1-hydroxiethyl)phenol as agonists of the b2 adrenergic receptor: o

20090082376 - Deuterium-enriched alogliptin: The present application describes deuterium-enriched alogliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082377 - Matrix metalloproteinase inhibitors: e

20090082380 - Deuterium-enriched rosuvastatin: The present application describes deuterium-enriched rosuvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082379 - Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors: e

20090082381 - Percutaneously absorbable ophthalmic preparation:

20090082383 - Deuterium-enriched buprenorphine: The present application describes deuterium-enriched buprenorphine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082382 - Deuterium-enriched naltrexone: The present application describes deuterium-enriched naltrexone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082384 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.... Agent: Knobbe Martens Olson & Bear LLP

20090082385 - Deuterium-enriched desloratidine: The present application describes deuterium-enriched desloratadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082386 - Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof: Provided is ascomycin that has a low level of an FK523 impurity, and pimecrolimus that has a low level of a 32-deoxy-32-epichloro-FK523 impurity, methods of preparing them, and the use of such pimecrolimus for preparing a pharmaceutical composition.... Agent: Kenyon & Kenyon LLP

20090082387 - Deuterium-enriched nvp-bez234: The present application describes deuterium-enriched NVP-BEZ235, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082388 - Co-administration of pimavanserin with other agents: As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are... Agent: Knobbe Martens Olson & Bear LLP

20090082389 - Pesticidal substituted piperidines: The invention relates to the use of piperidine derivatives encompassed from the general formula (I) for the control of pests, including arthropods and helminths, and a method for the control of pests.... Agent: Frommer Lawrence & Haug

20090082390 - Piperidine compounds for use as orexin receptor antagonist: This invention relates to N-aroyl cyclic amine derivatives and their use as pharmaceuticals, specifically as orexin receptor antagonists.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090082391 - Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments: The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one aminoalcohol-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the aminoalcohol-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090082392 - Substituted carboxylic acids: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090082393 - New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them: i

20090082394 - Tetrahydroisoquinoline derivatives to enhance memory function: The invention relates to the use of tetrahydroisoquinoline derivatives for the preparation of a medicament to enhance, maintain and/or restore all stages and/or types of short-, middle- and/or long-term memory.... Agent: Hoxie & Associates LLC

20090082396 - 5-aryl-4,5-dihydro-(1h)-pyrazolines as cannabinoid cb1 receptor agonists: e

20090082395 - Soluble epoxide hydrolase inhibitors: Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive,... Agent: Foley & Lardner LLP

20090082397 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and... Agent: Theravance, Inc.

20090082398 - Crystalline forms of fexofenadine hydrochloride and processes for their preparation: Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20090082399 - Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds which are Carbamate derivatives of formula I wherein X, B, P, Q5W, R1 and R2 are defined in the description. Invention compounds are useful for treating CNS or PNS disorders which are affected by the neuromodulatory effect of mGluR5 positive allosteric modulators such... Agent: Edwards Angell Palmer & Dodge LLP

20090082401 - Deuterium-enriched tiagabine: The present application describes deuterium-enriched tiagabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082400 - Soluble pyrone analogs methods and compositions: Methods and compositions are described that comprise pyrone analogs such as flavonoids and cyclodextrins including quercetin and quercetin derivatives and sulfoalkyl ether cyclodextrins. In some cases the compounds of the invention are administered with a therapeutic agent such as an analgesic. In some cases, treatment with the compositions of the... Agent: Wilson Sonsini Goodrich & Rosati

20090082402 - Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase: The invention relates to methods of treating or preventing a disease state associated with a genitourinary disorder using inhibitors of soluble epoxide hydrolase.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090082403 - Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same: wherein R1 represents hydrogen, halogen, amino, R11—NH— wherein R11 represents C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkoxy C1-6 alkyl, or C1-6alkoxycarbonyl C1-6 alkyl, R12—(CO)—NH— wherein R12 represents C1-6 alkyl group or C1-6 alkoxy C1-6 alkyl, C1-6 alkyl, hydroxy C1-6 alkyl, cyano C1-6 alkyl, C1-6 alkoxy, or C1-6 alkoxy C1-6 alkyl... Agent: Birch Stewart Kolasch & Birch

20090082404 - Benzimidazoles: Novel compounds of the formula I in which R1, R1′, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated in Claim 1 and are, for example, inhibitors of tyrosine kinases, for example TIE-2, and can be employed, for example, for the treatment of tumours... Agent: Arent Fox LLP

20090082406 - Cancer therapy: This invention relates to a method of regulating the cell cycle and treating cancer with a peroxisome proliferator-activated receptor γ agonist and a mevalonate pathway inhibitor or a mevalonate antagonist.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090082405 - Deuterium-enriched pioglitazone: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082407 - Pyridoxamine for the treatment of diabetic kidney disease: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090082408 - Novel heterocyclic derivatives: The present invention relates to novel heterocyclic derivatives of the general formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The present invention more particularly provides novel compounds of the general formula (I).... Agent: Ladas & Parry LLP

20090082409 - Steam stripping polymer dispersions to improve biocide stability: A process for stabilizing biocide compounds in a polymer dispersion requiring stripping of the dispersion using steam or an inert gas.... Agent: Rohm And Haas Company Patent Department

20090082410 - Constitutively translocating cell line: The present invention relates to agonist-independent methods of screening for compounds that alter GPCR desensitization. Included in the present invention are cell lines containing GRKs, in which GPCRs are desensitized in the absence of agonist; the GRKs may be modified. The present invention relates to methods to determine if a... Agent: Morgan, Lewis & Bockius, LLP

20090082411 - Pharmaceutical for prevention or treatment of bone metabolic disease: wherein R1 represents a C1-C4 alkyl; R2 and R3 are the same or different and each represent hydrogen or a C1-C4 alkyl; R4 represents hydrogen or a C1-C4 alkyl; R5 represents hydrogen, a C1-C4 alkyl, a C2-C5 alkanoyloxymethyl, 1-(C2-C5 alkanoyloxy)ethyl, a C1-C4 alkoxycarbonyloxymethyl, 1-(C1-C4 alkoxycarbonyloxy)ethyl, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl, a (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl or... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090082412 - Deuterium-enriched deferasirox: The present application describes deuterium-enriched deferasirox, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082413 - Deuterium-enriched letrozole: The present application describes deuterium-enriched letrozole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082414 - Deuterium-enriched viramidine: The present application describes deuterium-enriched viramidine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082415 - Topical treatment of cataracts in dogs: The topical carrier is formed from EDTA and deionized water containing about 2.5% carbomer, 1.5% glycerin, 0.02% EDTA and 0.1% benzalkonium chloride mixed to form a uniform emulsion. The concentration of the ARI in the topical carrier is preferably about 5-6%. The treatment includes administering to a dog an effective... Agent: Litman Law Offices, Ltd.

20090082416 - Deuterium-enriched bendamustine: The present application describes deuterium-enriched bendamustine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082417 - Deuterium-enriched sdx-101: The present application describes deuterium-enriched SDX-101, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082418 - Deuterium-enriched fluvastatin: The present application describes deuterium-enriched fluvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082419 - Deuterium-enriched tegaserod: The present application describes deuterium-enriched tegaserod, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082421 - Crystalline form b4 of atorvastatin magnesium and a process thereof: Crystalline polymorphic form B4 of Atorvastatin magnesium of FIG. 1 and processes for its preparation.... Agent: Harness, Dickey & Pierce, P.L.C

20090082420 - Deuterium-enriched vildagliptin: The present application describes deuterium-enriched vildagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082422 - Deuterium-enriched levetiracetam: The present application describes deuterium-enriched levetiracetam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082423 - Soluble epoxide hydrolase inhibitors: Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive,... Agent: Foley & Lardner LLP

20090082424 - Small molecule antagonists of bcl-2 family proteins: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds... Agent: Casimir Jones, S.c.

20090082425 - Compounds from myrothecium sp. for inhibiting the growth of cancer cells: The present invention relates to a tumor-inhibiting compound, in particular to verrucarin A and verrucarin J isolated from Myrothecium sp., and its use in inhibiting the growth of cancer cell including lung cancer, hepatic cancer and prostate cancer. Verrucarin A and verrucarin J in the present invention were applied in... Agent: Rabin & Berdo, PC

20090082426 - Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof: The present invention relates to dimers of artemisinin derivatives, to processes for the preparation of such dimers, to methods of treatment comprising administration of such dimers, and to intermediates to such dimers.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090082427 - Composition comprising wortmannin and its topical use for reducing human hair growth: A cosmetic and therapeutic method for reducing human hair growth comprises selecting an area of skin from which reduced hair growth is desired and applying to the area of skin a composition comprising wortmannin in an amount effective to reduce hair growth.... Agent: Traskbritt, P.C./reckitt Benckiser

20090082429 - Antimicrobial compositions and methods of use: A catechin is modified in at least one position (most preferably in the 3-position of the C-ring) to increase its lipophilicity. Contemplated catechins are demonstrated to have significantly improved antibacterial properties, likely due to catastrophic membrane damage.... Agent: Fish & Associates, PC Robert D. Fish

20090082428 - Spiroketals: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.... Agent: Seed Intellectual Property Law Group PLLC

20090082430 - Materials and methods for treating coagulation disorders: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090082431 - Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.... Agent: Bozicevic, Field & Francis LLP

20090082432 - Deuterium-enriched ramelteon: The present application describes deuterium-enriched ramelteon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082433 - Preventative treatment and remission of allergic diseases: The invention provides the use of at least one plant selected from plants of the family Zingiberaceae in the preparation of a medicament for use in the treatment or prophylaxis of allergic diseases. The plant is optionally selected from the genera Siphonochilus, Kaempferia, Cienkowskia and Cienkowskiella and the species is... Agent: Sheridan Ross PC

20090082434 - Dihydrobenzofuranyl alkanamine derivatives and methods for using same: e

20090082435 - Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders: Methods, compositions, and compounds for inhibiting monoacyglycerol lipase, and for treating pain, for modulating stress-induced analgesia or for treating stress-induced disorders in mammals are provided.... Agent: Townsend And Townsend And Crew, LLP

20090082436 - Deuterium-enriched rivastigmine: The present application describes deuterium-enriched rivastigmine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082438 - Coordination compound composed of diaminocyclohexane platinum (ii) and block copolymer and anti-cancer agent comprising the same: The invention discloses a coordination compound comprising (1,2-diaminocyclohexane)platinum (II) moiety and poly(ethylene glycol)-block-poly(glutamic acid) copolymer moiety; and its use as an anti-cancer agent. The characteristic feature lies in the use of a copolymer whose poly(glutamic acid) segment has a chain length consisting of, on an average, less than 35 repeating... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090082437 - Use of oxaliplatin for enhancing radiosensitivity in radiotherapy of cervical cancer: The present invention relates to a method for enhancing radiosensitivity in radiotherapy of cervical cancer by administering to cervical cancer cells an effective amount of oxaliplatin. Radiation combined with pretreatment of oxaliplatin according to the present invention helps to enhance the cytotoxicity of radiation and result in augmenting radiation-induced mitotic... Agent: Wpat, PC Intellectual Property Attorneys

20090082439 - Organic light-emitting device and display apparatus: e

20090082441 - Deuterium-enriched tesaglitazar: The present application describes deuterium-enriched tesaglitazar, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082440 - Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use: Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders,... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090082442 - Deuterium-enriched lubiprostone: The present application describes deuterium-enriched lubiprostone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082443 - Use of fatty acid esters of glycerol combined with polylysine against gram-negative bacteria: The present invention relates to a method for the prevention and/or reduction of the presence, growth and/or activity of gram-negative bacteria comprising application of a composition comprising glycerol-based fatty acid esters and polylysine and/or salts of polylysine, wherein said glycerol-based fatty acid ester is used as antibacterial agent. The present... Agent: Oliff & Berridge, PLC

20090082444 - Compositions for the treatment of blood disorders: The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with... Agent: Swanson & Bratschun, L.L.C.

20090082445 - Gossypol co-crystals and the use thereof: This invention relates to compositions comprising co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid which are useful as inhibitors of Bcl-2 family proteins. The invention also relates to the use of co-crystals of (−)-gossypol with a C1-8 carboxylic acid or C1-8 sulfonic acid for inducing apoptosis... Agent: Casimir Jones, S.c.

20090082448 - Method for placental exfoliation using oxo-arachidonic acid or the like: A composition for placental exfoliation and a method for placental exfoliation. The composition for placental exfoliation contains an arachidonic acid derivative or the like, and the method for placental exfoliation comprises the step of administering an arachidonic acid derivative or the like to a mammal after the fetal delivery.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090082447 - Pharmaceutical compositions containing omega 3 fatty acids: Pharmaceutical composition comprising a liquid oil rich in omega-3 polyunsaturated fatty acids which is absorbed on a silica-type support. The composition so obtained has the characteristics of a powder when the oil:silica ratio is of the order of 3:1 while at the same time allowing the required daily dose of... Agent: The Firm Of Hueschen And Sage

20090082446 - Use of hydroxyoleic acid and related compounds in the manufacture of drugs: Use of hydroxyoleic acid and its analogous compounds in the manufacture of drugs. Describes the use of hydroxyoleic acid and its analogs of general formula I: COOH—CHR—(CH2)m—CH═CH—(CH2)n—CH3, in which m and n have, independently, a value of 0-15 and R can be any residue with molecular weight below 200 Da,... Agent: Ladas & Parry

20090082449 - Spray-drying process for producing a dry caritine powder or granulate: A process for preparing a dry substantially pure and/or technical carnitine powder or granulate, from a substantially unpurified starting material containing a carnitine compound.... Agent: Fisher, Christen & Sabol

20090082450 - Deuterium-enriched diclofenac: The present application describes deuterium-enriched diclofenac, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082452 - Deuterium-enriched lumiracoxib: The present application describes deuterium-enriched lumiracoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082451 - Use of thyroid hormone conversion inhibitors: The present invention is directed to the use of thyroid hormone conversion inhibitors to treat hyperproliferative skin disorders, preferably their use in topical admixtures.... Agent: Knobbe Martens Olson & Bear LLP

20090082453 - Exogenous methyl dihydrojasmonate for prevention and control of biotic attack in plants: e

20090082454 - Deuterium-enriched disufenton: The present application describes deuterium-enriched disufenton, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082455 - Therapeutic agent for ophthalmic disease: An agent for the prevention, treatment and/or inhibition of progression of an ophthalmic disease and an agent for the protection of an optic nerve, each of which comprises (2R)-2-propyloctanoic acid or a salt or prodrug thereof in which an amount per dose is from 0.3 ng to 5000 mg. The... Agent: Sughrue-265550

20090082456 - Soluble epoxide hydrolase inhibitors: Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive,... Agent: Foley & Lardner LLP

20090082457 - Derivatives of n-(arylamino) sulfonamides as inhibitors of mek: This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20090082458 - Deuterium-enriched aliskiren: The present application describes deuterium-enriched aliskiren, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082459 - Deuterium-enriched guanfacine: The present application describes deuterium-enriched guanfacine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082460 - Polyamide-polyether block copolymer: Copolymers having linked internal polyether blocks and internal polyamide blocks have advantageous physical properties and solvent-gelling abilities. The copolymer may be prepared from a reaction mixture that contains 1,4-cyclohexane dicarboxylic acid (CHDA) and poly(alkyleneoxy)diamine (PAODA). Optionally, the reaction mixture contains no monofunctional compound reactive with either amine or carboxylic acid... Agent: Arizona Chemical Company C/o Bo Segers

20090082462 - Deuterium-enriched armodafinil: The present application describes deuterium-enriched amodafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082461 - Deuterium-enriched modafinil: The present application describes deuterium-enriched modafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082463 - N-substituted phenylacetamide derivative and pharmaceutical composition containing the same: e

20090082464 - Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use: Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090082465 - Deuterium-enriched lisdexamfetamine: The present application describes deuterium-enriched lisdexamfetamine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082466 - Abuse resistant and extended release formulations and method of use thereof: The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioids, extended release pharmaceutical compositions of opioids and extended release abuse resistant pharmaceutical compositions of opioids and the use thereof for the treatment of pain. The present invention is also directed to extended release pharmaceutical compositions... Agent: Theraquest Biosciences, Inc.

20090082467 - Treatment of migraine headaches using antiestrogens: A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to... Agent: Norris, Mclaughlin & Marcus, Pa

20090082468 - Deuterium-enriched levalbuterol: The present application describes deuterium-enriched levalbuterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082469 - Deuterium-enriched terbinafine: The present application describes deuterium-enriched terbinafine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082470 - Stat3 inhibiting compositions and methods: STAT3 inhibiting molecules and composition prevent intraoccular neovascularization and inflammation. STA-21-related compounds, for example CLT-005, are shown to prevent dimerization of STAT3, thereby inhibiting STAT3 activity. Inhibition of activity is shown to reduce intraoccular inflammation and neovascularization, symptoms of eye-related diseases such as age-related macular degeneration. Inhibition of STAT3 prevents... Agent: Greenberg Traurig LLP (la)

20090082471 - Deuterium-enriched fingolimod: The present application describes deuterium-enriched fingolimod, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090082472 - Hand sanitizer and method of preparation: A sanitizing composition or hand gel composition having a blend of SDA and Isopropyl Alcohol to kill germs and bacteria, a thickener, such as an acrylic polymer, a stabilizer or polymer acrylic acid neutralizer, such as polyoxyethylene (15) coconut alkylamine, octyl isononanoate as an emollient, glycerin as an additional moisturizer,... Agent: Litman Law Offices, Ltd.

20090082473 - Composition comprising resveratol and its topical use thereof for reducing human hair growth: A cosmetic and therapeutic method for reducing human hair growth comprises selecting an area of skin from which reduced hair growth is desired and applying to the area of skin a composition comprising resveratrol in an amount effective to reduce hair growth.... Agent: Merchant & Gould PC

  
03/19/2009 > patent applications in patent subcategories. listing by industry category

20090075862 - Method for providing glutamine: A method of providing glutamine to a patient. A nutritional composition which includes whey protein, or a protein mixture which simulates the amino acid profile of whey protein, as a protein source is enterally administered to the patient. The whey protein may be a hydrolyzed whey protein. The patient may... Agent: Bell, Boyd & Lloyd LLP

20090075861 - Systems and methods of removing and managing heavy metals: Systems and methods remove and manage heavy metals. In one implementation, an exemplary method can be applied to food processing and food consumption to remove heavy metals such as mercury, lead, uranium and cadmium before absorption by a living organism. The exemplary method exposes the food to a heavy-metal binding... Agent: Mark Farrell Farrell Patent Law PC

20090075860 - Transdermal absorption enhancer: An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090075863 - Periosteal tissue grafts: This document relates to methods and materials involved in making and using periosteal tissue grafts in vivo. For example, materials and methods for obtaining grafts comprising periosteal tissue are provided.... Agent: Fish & Richardson P.C.

20090075864 - Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators: Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090075866 - Method to enhance hemodynamic stability using oxygen carrying compositions: The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance... Agent: The Nath Law Group

20090075865 - Novel medicament for ameliorating dyskinesia: A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention... Agent: Birch Stewart Kolasch & Birch

20090075868 - Synthetic peptide materials for joint reconstruction, repair and cushioning: In joint reconstruction, repair and cushioning applications, a synthetic polypeptide material is useful that contains cross-linked polypeptides that are modeled on human elastin or other fibrous proteins. The polypeptides comprise at least three consecutive beta-sheet/beta-turn structures and at least one amino acid residue that participates in cross-linking.... Agent: Foley And Lardner LLP Suite 500

20090075867 - Triazine compounds and compositions thereof for the treatment of cancers: Compounds useful in the treatment of metastatic melanoma and other cancers containing a triazine ring scaffold are described. These compounds may be classified into two groups: (1) two disubstituted triazine rings are covalently linked by an organic linker to each other and (2) one trisubstituted triazine ring.... Agent: Nixon & Vanderhye, PC

20090075870 - Deuterium-enriched caspofungin: The present application describes deuterium-enriched caspofungin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075869 - Hcv ns3 protease inhibitors: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.... Agent: Merck And Co., Inc

20090075880 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090075876 - Altered insulin-like growth factor binding proteins: Altered IGFBPs are able to bind IGF, but the release is inhibited by resistance to protease cleavage and/or reduced binding to extracellular matrix (ECM). Alterations have been made in IGFBP-2 to the linker domain in particular and to two amino acid motifs found to be important for ECM binding. IGF-1... Agent: Foley And Lardner LLP Suite 500

20090075885 - Antitumor effect of mutant bik: The present invention regards mutant forms of Bik that comprise anti-cell proliferation and/or pro-apoptotic activities. In particular embodiments, the Bik polypeptides comprise a substitution at Thr33 and Ser35 and, in some embodiments, phosphorylation at these sites is inhibited. In more particular embodiments, these forms are useful for cancer therapy, particularly... Agent: Fulbright & Jaworski, LLP

20090075888 - Cardiovascular and brain cell therapy using intracellular ryanodine receptor modulation by the estrogen receptor beta: The present invention includes compositions and methods for screening for a candidate substance with ryanodine receptor (RyR)-modulatory activity, the method including: determining the ion-conducting ability and ability to change the concentration of the free cytoplasmic intracellular Ca2+ by the RyR modulated by Estrogen receptor-β (ERβ) in cells or cell membranes... Agent: Chalker Flores, LLP

20090075883 - Compositions for the treatment of cancer, and methods for testing and using the same: A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood... Agent: Klauber & Jackson

20090075886 - Dendritic cell stimulatory factor: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T... Agent: Sughrue Mion, PLLC

20090075881 - Fibrin gel for controlled release of pdgf and uses thereof: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.... Agent: Baxter Healthcare Corporation

20090075873 - Gastrin compositions and formulations, and methods of use and preparation: The present invention concerns six novel variants of alternative splicing of the CD40 receptor.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090075884 - Human il-17f and other il-17f-related proteins and methods related thereto: Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.... Agent: Fitzpatrick Cella (wyeth)

20090075893 - Inhibition of angiogenesis by neutrophil alpha-defensins: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis mediated by alpha-defensins.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090075889 - Iren protein, its preparation and use: There are provided DNA sequences encoding TRAF binding proteins, proteins encoded thereby, and their use in the treatment or prevention of pathological conditions associated with NF-κB induction, or an activity mediated by a TRAF.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090075890 - Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified... Agent: Jones Day

20090075891 - Methods and dressings for sealing internal injuries: Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.... Agent: Duane Morris LLP

20090075877 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or versants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific... Agent: Robins & Pasternak

20090075872 - Methods and means: This invention relates to methods and means for the stimulation of phagocytosis and in particular to the phagocytosis of apoptotic cells, and discloses a role for the protein product of the apoE gene (apolipoproteinE) as a regular of apoptotic cell clearance. ApoE mimetics and other compounds which stimulate the clearance... Agent: Schwegman, Lundberg & Woessner, P.A.

20090075874 - Methods for construction and screening of libraries of chemokine variants: The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods... Agent: Birch Stewart Kolasch & Birch

20090075878 - Methods for generating and screening fusion protein libraries and uses thereof: The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that... Agent: Bereskin And Parr

20090075894 - Novel bacillus thuringiensis gene with coleopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20090075879 - Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus: The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID No1, a peptide B having at least the... Agent: Clark & Elbing LLP

20090075875 - Protection against lung fibrosis by up-regulating the function or expression of caveolin-1: Disclosed are compositions and methods for the treatment of fibrosis. Also disclosed are methods of screening for agents that treat fibrosis.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090075882 - Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis: Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis, are also provided.... Agent: Klarquist Sparkman, LLP

20090075895 - Stabilised solid composition of modified factor vii: The invention concerns a composition comprising; i) Modified Factor VII; ii) an agent suitable for keeping the pH of said composition in the range of 4 to 7 when said composition is dissolved in water; and iii) a moisture content of at the most 3%.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090075892 - Synthetic pulmonary surfactant peptides: The present invention is directed to a reconstituted surfactant comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B. The invention is also directed to the pharmaceutical compositions thereof and to a use thereof in the treatment... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090075887 - Treatment with kallikrein inhibitors: Methods, kits and compositions are disclosed that include a non-naturally occurring kallikrein inhibitor and optionally a viscosupplement for the treatment of joint pathology.... Agent: Lowrie, Lando & Anastasi, LLP

20090075898 - Complement c3a derived peptides and uses thereof: Peptides corresponding partially to positions 55-64 of the sequence of the complement component peptide C3a are capable of preventing and treating mast cell- and basophil-mediated disorders by inhibiting IgE- or IgG-mediated triggering and/or by inhibiting the FcεRI- and/or FcγR-induced secretory response, while obviating the anaphylatoxic response. These peptides are useful... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090075896 - Novel antihypertensive peptide and use thereof: The present invention provides a novel antihypertensive peptide. Also provided are pharmaceutical and food compositions containing the antihypertensive peptide for treating hypertension or cardiovascular disease.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090075897 - Peptides derived from the c2 domain of epsilon pkc and methods of use, thereof: Peptides derived from the C2 regions of εPKC and methods of use, thereof, are described. These peptides modulate the activity of εPKC in an animal model of acute ischemic heart disease.... Agent: Perkins Coie LLP

20090075899 - Inhibiting collagen-induced platelet aggregation and activation with peptide variants: The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090075902 - Inhibiting the signs of aging by inhibiting nf-kappa b activation: The present invention relates to methods and compositions for reducing and/or delaying one or more signs of aging which comprise inhibiting NF-kappa B activation. It is based, at least in part, on the discovery that a peptide which inhibits IKK-β interaction with NEMO, linked to a transducing peptide, inhibits the... Agent: Baker Botts L.L.P.

20090075903 - Method of using substance p analogs for treatment amelioration of myelodysplastic syndrome: Myelodysplastic syndromes can be treated or ameliorated by the administration of substance P analogs as disclosed herein.... Agent: Jones Day

20090075901 - Peptides for activation and inhibition of deltapkc: Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as... Agent: Morrison & Foerster LLP

20090075900 - Therapeutic agent for motor neuron disease: An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to... Agent: Birch Stewart Kolasch & Birch

20090075904 - Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use: Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated... Agent: Foley And Lardner LLP Suite 500

20090075905 - Anticancer compounds and methods: The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide... Agent: Medlen & Carroll, LLP

20090075906 - Oligopeptides and compositions containing the oligopeptides: Oligopeptides according to formula (I) and/or (II), R1-Tyr-Pro-Trp-Phe-NH2 (I); R1-Tyr-Pro-Phe-Phe-NH2 (II), wherein R1 is linked to the NH2-group of the amino-terminal part of Tyr and is selected from the group consisting of —H; a linear saturated or unsaturated or branched saturated or unsaturated acyl group having 1 to 24 carbon... Agent: Fox Rothschild LLP

20090075907 - Synthetic peptide amides: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090075908 - Agent for strengthening calcium containing tissue and use thereof: The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090075909 - Derivatives of pentose monosaccharides as anti-inflammatory compounds: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention... Agent: Ranbaxy Inc.

20090075910 - Deuterium-enriched fondaparinux: The present application describes deuterium-enriched fondaparinux, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075911 - Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring: The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the... Agent: Clark & Elbing LLP

20090075913 - Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent: 3-O-β-D-Glucopyranosyl-4-methylergost-7-en-3-ol or a composition containing 0.001% by mass or more of the aforementioned compound, which is an extract of a plant of the family Liliaceae containing the compound or a fraction thereof, is used as an active ingredient of a hyperglycemia improving agent.... Agent: Knobbe Martens Olson & Bear LLP

20090075912 - Use of timosaponin bii in the preparation of a medicament or product for the prevention and treatment of stroke: The invention disclosed the use of timosaponin BII in the preparation of a medicament or product for the prevention and treatment of stroke. The experiments prove that timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury... Agent: Alston & Bird LLP

20090075914 - Deuterium-enriched odiparcil: The present application describes deuterium-enriched odiparcil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075915 - 6,11-bicyclolides: bridged biaryl macrolide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20090075917 - Deuterium-enriched telithromycin: The present application describes deuterium-enriched telithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075916 - Use of macrolide derivatives for treating acne: This invention relates to 14-membered macrolide derivatives for treating or preventing acne vulgaris and associated inflammatory conditions. Also provided herein are medicaments or pharmaceutical compositions comprising one or more 14-membered macrolide derivatives together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixture thereof, and methods for treating or... Agent: Ranbaxy Inc.

20090075918 - Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine: Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine. A veterinarian formulation comprising of organics salts of levamisole, more specifically to the disophenolat salt of levamisole and the nitroxynil-salt of levamisole with avermectines and milbemycines and its use in treatment of helminthiasis... Agent: Smith, Gambrell & Russell

20090075919 - Anti-neoplastic compositions comprising extracts of black cohosh: The present invention provides a composition for use in treating or preventing neoplasia, comprising an effective actein. The present invention also provides a composition for use in treating or preventing neoplasia, comprising an effective anti-neoplastic amount of an ethyl acetate extract of black cohosh. The present invention further provides a... Agent: Bryan Cave LLP

20090075920 - Deuterium-enriched decitabine: The present application describes deuterium-enriched decitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075921 - Bone/joint disease sensitivity gene and use thereof: The present invention provides the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of calmodulin, the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of asporin, and a diagnostic method for genetic susceptibility to bone and joint diseases... Agent: Edwards Angell Palmer & Dodge LLP

20090075928 - G-quartet oligonucleotides that target hypoxia-inducible factor 1-a (hif1a ): The present invention concerns particular G-quartet oligonucleotides that are employed for the treatment and/or prevention of cancer. In specific cases, the G-quartet oligonucleotides inhibit HIF-1α.... Agent: Fulbright & Jaworski, LLP

20090075929 - Ig20 splice variants therapeutics for cancer: Methods and compositions inhibit the growth of cancer cells by selectively down-regulating the expression of an IG20 splice variant including MADD. Specific knock-down of MADD splice variant resulted in the apoptosis of cancer cells. Interfering RNAs including small hairpin RNAs (shRNA) to down-regulate MADD expression in vivo are disclosed. Inhibition... Agent: Barnes & Thornburg LLP

20090075926 - Method for identifying and manipulating cells: The present application discloses a method of isolating or selecting stem cells from a mixed population containing stem cells, which includes the population of cells with a ligand specific for a truncated MUC1 receptor, wherein the presence of the truncated MUC1 receptor on the cells indicates that they are stem... Agent: Jhk Law

20090075925 - Methods and compositions related to apobec-1 expression: Disclosed are methods and compositions related to ACF and to APOBEC-1.... Agent: Clark G. Sullivan Arnall Golden Gregory LLP

20090075923 - Methods of treatment of renal disease: The invention is directed to a process of identifying a compound capable of inhibiting the activity of a human Ax1 receptor that comprises contacting the Ax1 receptor or cells expressing the Ax1 receptor with the compound; measuring the Ax1 receptor activity in the presence of the compound; and comparing the... Agent: Cooper & Dunham, LLP

20090075924 - Modulation of apolipoprotein (a) expression: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20090075922 - Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are... Agent: Swanson & Bratschun, L.L.C.

20090075927 - Sweet taste receptors: This invention provides novel genes and polypeptides of the sweet receptor family, methods for production of the polypeptides, methods for screening compounds that specifically bind to and/or modulate the activity of these polypeptides; and antibodies specific for the polypeptides.... Agent: Genomics Institute Of The Novartis Research Foundation

20090075930 - Deuterium-enriched nelarabine: The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075931 - Deuterium-enriched capecitabine: The present application describes deuterium-enriched capecitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075932 - Method of selectively inhibiting pkciota: PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1α,2β,3β,4α)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota.... Agent: Smith Hopen, Pa

20090075935 - Composition comprising at least one c-glycoside derivative and at least one hyaluronic acid and its cosmetic use: The present invention relates to a topical cosmetic and/or dermatological composition comprising, in a physiologically acceptable medium, at least one hyaluronic acid or a derivative thereof and at least one C-glycoside derivative.... Agent: Oliff & Berridge, PLC

20090075933 - Cytocompatible alginate gels: The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.... Agent: Squire, Sanders & Dempsey LLP

20090075934 - Use of sulfated oligosaccharides as slimming cosmetic ingredients: e

20090075936 - Proteasome inhibitors and methods of using the same: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome... Agent: Cephalon, Inc.

20090075937 - Lhrh antagonists for the treatment of lower urinary tract symptoms: The present invention provides at least one LHRH antagonist for the treatment or prophylaxis of at least one lower urinary tract symptom in mammals which is to be administered in an intermediate dose, which does not cause chemical (hormonal) castration.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090075938 - Treatment of duchenne muscular dystrophy: There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C═W, NR4, NC(═O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4,... Agent: Jones Day

20090075939 - Novel hiv reverse transcriptase inhibitors: e

20090075940 - Deuterium-enriched risedronate: The present application describes deuterium-enriched risedronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075941 - Treating neoplasms: Methods of treating a subject with neoplasm (e.g., mesothelioma) or at risk of developing neoplasm by administering a mevalonate pathway inhibitor such as a nitrogen-containing bisphosphonate are disclosed. Examples of nitrogen-containing bisphosphonates include alendronate, ibandronate, minodronate, neridronate, olpadronate, pamidronate, risedronate, and zoledronate. The methods can further include the administration of... Agent: Fish & Richardson P.C.

20090075942 - Deuterium-enriched fosamprenavir: The present application describes deuterium-enriched fosamprenavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075871 - Modified thioredoxin: The present invention relates to a human modified thioredoxin composed of any of the following polypeptides: (a) a polypeptide modified by alteration or chemical modification of a cysteine residue at position 35 with another amino acid in an amino acid sequence of SEQ ID NO:2; and (b) a polypeptide having... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090075943 - Combretastatin analogs with tubulin binding activity: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting... Agent: Oxigene, Inc. C/o Law Offices Of Karen E. Flick

20090075944 - Deuterium-enriched ibandronate: The present application describes deuterium-enriched ibandronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075945 - Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents: e

20090075946 - Novel triterpenic acid derivative and preparation for external application for skin comprising the same: In a triterpenic acid having hydroxyl groups, at least one of the hydroxyl groups is phosphorylated to produce a phosphorylated triterpenic acid and/or a salt thereof, thereby improving the solubility of the triterpenic acid in a preparation for external application for the skin and allowing the physiological activity of the... Agent: Knobbe Martens Olson & Bear LLP

20090075947 - Deuterium-enriched fospropofol: The present application describes deuterium-enriched fospropofol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075948 - Compositions and methods for regulating cellular protection: The invention provides a method of inducing a protective response in cells by activating a heat shock response, via heat shock transcription factor (HSF), without stressing the cells. The invention is based on the surprising discovery that HSF can be activated in non-stressed cells by disrupting interaction with the repressive... Agent: Karen S. Canady Canady & Lortz LLP

20090075950 - Dosage forms containing a ppi, nsaid and a buffer: Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form.... Agent: Dykema Gossett PLLC

20090075949 - Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases: The invention relates to a method of treating and preventing thromboembolic disorders, comprising administering dipyridamole in combination with an antithrombotic selected from direct thrombin inhibitors, factor Xa inhibitors and combined thrombin/factor Xa inhibitors to a patient, pharmaceutical compositions suitable for this method of treatment as well as the use of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090075951 - Methods and reagents for the treatment of inflammatory disorders: The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a tricyclic compound and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing a tricyclic compound and a corticosteroid or other... Agent: Clark & Elbing LLP

20090075952 - Nitroderviatives as drugs for diseases having an inflammatory basis: Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-X1-L-(W)p-NO2 wherein A contains the radical of a drug, X1 and W are bivalent radicals, L is a covalent bond or oxygen, sulphur, NR1c wherein R1c is H or... Agent: Arent Fox LLP

20090075953 - Deuterium-enriched ed-71: The present application describes deuterium-enriched ED-71, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075954 - Soft anticholinergic esters: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; R is C1-C8 alkyl, straight or branched chain; and X− is an anion with a single negative charge; and wherein each asterisk marks a chiral center; said compound having the... Agent: Buchanan, Ingersoll & Rooney PC

20090075955 - Therapeutic regimens for the treatment of immunoinflammatory disorders: The invention features pharmaceutical compositions and dosing regimens for the treatment of immunoinflammatory disorders.... Agent: Clark & Elbing LLP

20090075958 - Clobetasol propionate shampoos for the treatment of seborrheic dermatitis of the scalp: Seborrheic dermatitis is effectively/safely treated by topically applying a corticosteroid shampoo, notably a clobetasol propionate shampoo, onto the scalp of a human subject afflicted therewith.... Agent: Buchanan, Ingersoll & Rooney PC

20090075956 - Genetic risk assessment in heart failure: impact of the genetic variation of nos3: The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance;... Agent: Wilmerhale/dc

20090075957 - Xanthohumol compositions and methods of using same: The present invention provides compositions comprising an effective amount of xanthohumol and honokiol. The present invention comprises compositions comprising an effective amount of xanthohumol and genistein. The present invention comprises compositions comprising an effective amount of xanthohumol and guggulsterone. The compositions of the present invention may be effective to decrease... Agent: Troutman Sanders LLP

20090075959 - Deuterium-enriched ciclesonide: The present application describes deuterium-enriched ciclesonide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075960 - Method of treating gaucher disease: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090075961 - Testosterone oral dosage formulations and associated methods: Solid oral dosage forms of testosterone and methods for the preparation thereof are disclosed and described. The solid oral dosage form may include a therapeutically effective amount of testosterone in a substantially solid polyethylene glycol carrier. Such a form has been found to alleviate many of the undesirable consequences of... Agent: Hedman & Costigan P.C.

20090075962 - Growth stimulant compositions: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which... Agent: Intervet/schering-plough Animal Health Patent Department

20090075964 - Fragrance compositions and other compositions which contain naturally occurring substances found in corals: This invention is generally related to the fields of fragrance compositions, personal care products, and home consumer products. This invention also relates to 20-pregnenes, in particular those found naturally occurring in corals and which affect mood in humans, to the incorporation of these 20-pregnene compounds into various compositions, and to... Agent: Morrison & Foerster LLP

20090075963 - Transdermal hormone spray: The present invention provides a transdermal spray drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone which comprises applying an effective... Agent: Kv Pharmaceutical Company

20090075965 - Deuterium-enriched amoxicilin: The present application describes deuterium-enriched amoxicilin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075966 - Deuterium-enriched tazobactam: The present application describes deuterium-enriched tazobactam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075967 - Deuterium-enriched ceftriaxone: The present application describes deuterium-enriched ceftriaxone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075969 - Deuterium-enriched doripenem: The present application describes deuterium-enriched doripenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075968 - Cetp inhibitors: e

20090075970 - Thieno-and furo-pyrimidine modulators of the histamine h4 receptor: Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.... Agent: Philip S. Johnson Johnson & Johnson

20090075971 - Derivatives of 2-alkoxy-3,4,5-trihydroxy-alkyl amides, preparation and use thereof, and compositions containing the same: The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide derivatives, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation of such compounds, and to intermediate precursors to such compounds.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090075972 - Use of midostaurin for treating gastrointestinal stromal tumors: The present invention relates to the use of midostaurin, in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of gastrointestinal stromal tumors, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of... Agent: Novartis Corporate Intellectual Property

20090075973 - Benzo-fused heterocycles: e

20090075974 - Agent for prophylaxis and treatment of pancreatitis: Disclosed is a pharmaceutical composition for prophylaxis and treatment of pancreatitis comprising a 5-HT2A receptor antagonist as an effective component, wherein the binding activity (pKi) of the 5-HT2A receptor antagonist to a 5-HT2A receptor is higher at least by 1.0 than the binding activities to a 5-HT2B receptor and a... Agent: Pearne & Gordon LLP

20090075975 - Arylsulfonamides and uses related thereto: Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:... Agent: Foley And Lardner LLP Suite 500

20090075976 - Association between an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor: The present invention relates to the association of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also to pharmaceutical compositions containing them, and to methods of treating vascular complications associated with diabetes, with atherothrombotic diseases, with hyperlipidaemia, with hypertension, with chronic venous diseases, with inflammation, with metabolic syndrome associated... Agent: The Firm Of Hueschen And Sage

20090075977 - Deuterium-enriched mk0974: The present application describes deuterium-enriched MK-0974, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075978 - Substituted propiolic acid amides and their use for producing drugs: The present invention relates to substituted propiolic acid amides, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20090075980 - Pyrazolopyridines and analogs thereof: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090075979 - Cetp inhibitors: Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or... Agent: Merck And Co., Inc

20090075981 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions... Agent: Ropes & Gray LLP

20090075982 - Piperazine compounds: e

20090075983 - Novel diazabicycloalkane derivatives and their medical use: This invention relates to novel diaza-bicyclo-alkane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as... Agent: Birch Stewart Kolasch & Birch

20090075984 - Materials and methods relating to protein aggregation in neurodegenerative disease: The present invention is directed to methods for the treatment or prophylaxis of a tauopathy comprising administering to a patient in need thereof a medicament comprising a phenothiazine.... Agent: Foley And Lardner LLP Suite 500

20090075985 - Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease: e

20090075986 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20090075987 - Alkylacetylene substituted acyltryptophanols: v

20090075988 - Cyanoisoquinoline: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The... Agent: Darby & Darby P.C.

20090075990 - Aerosol formulation for inhalation containing an anticholinergic agent: The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X− represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090075991 - Deuterium-enriched efavirenz: The present application describes deuterium-enriched efavirenz, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075989 - Non-steroidal progesterone receptor modulators: e

20090075992 - Pteridine derivatives as nitric oxide synthase activators: The present invention relates to the use of pteridine derivatives as nitric oxide synthase activators. In particular, the derivatives find use in the treatment of diseases associated with endothelial dysfunction such as cardiovascular diseases.... Agent: Alston & Bird LLP

20090075994 - Deuterium-enriched radafaxine: The present application describes deuterium-enriched radafaxine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075993 - Pharmaceutically effective compounds: The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions comprising the same, and the use thereof in the preparation of pharmaceutical compositions for the treatment of vascular diseases.... Agent: Ropes & Gray LLP

20090075998 - 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors: or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated... Agent: Merck And Co., Inc

20090075997 - Deuterium-enriched satavaptan: The present application describes deuterium-enriched satavaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090075996 - Heterotetracyclic compounds as tpo mimetics: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.... Agent: Genomics Institute Of The Novartis Research Foundation

20090075995 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: e

20090075999 - Oxygen linked pyrimidine derivatives: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be... Agent: Connolly Bove Lodge & Hutz LLP

20090076000 - Deuterium-enriched mycophenolate mofetil: The present application describes deuterium-enriched mycophenolate mofetil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076002 - Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments: The invention relates to amino alcohol-substituted arylthienopyrimidinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one amino alcohol-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the amino alcohol-substituted arylthienopyrimidinones of the invention and their derivatives as... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090076001 - Substituted 4,5,6,7 -tetrahydro-isoxazolo[4,5-c]pyridine compounds and use thereof for producing medicaments: The present invention relates to substituted 4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridine compound corresponding to formula I, methods for producing them, to medicaments containing these compounds, the use of these compounds for producing medicaments and related treatment methods... Agent: Crowell & Moring LLP Intellectual Property Group

20090076003 - Phthalazine derivatives with angiogenesis inhibiting activity: The invention relates to new phthalazine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof alone or in combination with one or more other pharmaceutically active compounds for the treatment of a disease, especially of... Agent: Novartis Institutes For Biomedical Research, Inc.

20090076004 - Indoles useful in the treatment of inflammation: There is provided compounds of formula (I), wherein X1, Q, T, Y, R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family... Agent: Morgan Lewis & Bockius LLP

20090076005 - Kinase inhibitor compounds: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.... Agent: Edwards Angell Palmer & Dodge LLP

20090076006 - Hsp90 inhibitors containing a zinc binding moiety: The present invention relates to HSP90 inhibitors containing a zinc binding moiety and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20090076007 - Deuterium-enriched aprepitant: The present application describes deuterium-enriched aprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076008 - Deuterium-enriched fosaprepitant: The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076009 - Thiazole derivatives and their use as anti-tumour agents: or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme... Agent: Morgan Lewis & Bockius LLP

20090076010 - Deuterium-enriched lamotrigine: The present application describes deuterium-enriched lamotrigine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076011 - Deuterium-enriched tirapazamine: The present application describes deuterium-enriched tirapazamine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076013 - Deuterium-enriched sitagliptin: The present application describes deuterium-enriched sitagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076014 - Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.... Agent: Marshall, Gerstein & Borun LLP

20090076012 - Modulation of pathogenicity: e

20090076017 - Deuterium-enriched trabectedin: The present application describes deuterium-enriched trabectedin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076016 - Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases: Jorumycin, renieramycin, safracin and saframycin related compounds formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.... Agent: King & Spalding

20090076015 - Tricyclic spiro compound comprising acyl group bound to nitrogen atom in the ring: It is intended to provide an anticoagulant that has an extremely excellent FXa inhibitory action and an extremely weak hERG channel inhibitory action and can be orally administered, which is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.... Agent: Birch Stewart Kolasch & Birch

20090076018 - Deuterium-enriched ranolazine: The present application describes deuterium-enriched ranolazine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076019 - Methods for treating neurological disorders or damage: A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators... Agent: Howson And Howson

20090076020 - Cyclopropyl amide derivatives 978: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090076021 - Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease: A therapeutic combination, useful in a co-therapy method for improving cardiovascular performance and/or treating cardiovascular diseases, is provided comprising a first agent and a second agent, wherein the first agent comprises a histone deacetylase inhibiting agent and the second agent comprises at least one nuclear hormone receptor ligand.... Agent: Harness, Dickey, & Pierce, P.l.c

20090076023 - Local anesthetic methods and kits: Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090076022 - Tartrate salts of quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20090076024 - Episomal fusion gene: The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and... Agent: Nixon & Vanderhye, PC

20090076025 - Deuterium-enriched dasatinib: The present application describes deuterium-enriched dasatinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076026 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, f, W, Q, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds... Agent: Theravance, Inc.

20090076027 - Deuterium-enriched lurasidone: The present application describes deuterium-enriched lurasidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076028 - Deuterium-enriched itraconazole: The present application describes deuterium-enriched itraconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076029 - Compounds and methods for treating obesity: Methods for selection of compounds for treatment of obesity, compounds selected by the disclosed methods, and methods of treatment of obesity, wherein a selective melanocortin-4 receptor compound is identified, which compound is further characterized in that it attenuates the binding of both an agonist, including alpha-melanocyte stimulating hormone, and an... Agent: Morgan Lewis & Bockius LLP

20090076030 - Piperazine compounds: t

20090076032 - Derivatives of 18beta-glycyrrhetinic acid: The present invention relates to novel derivatives of 18β-glycyrrhetinic acid and methods of synthesising the derivatives. Also included within the scope of the present invention are pharmaceutical compositions comprising the derivatives of the present invention and medical uses of the derivatives, including their use in inhibiting enzymes such as retinol... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090076031 - Deuterium-enriched bortezomib: The present application describes deuterium-enriched bortezomib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076033 - Method for treating atherosclerosis employing an ap2 inhibitor and combination: A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatheroscletotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090076034 - Deuterium-enriched bms-690514: The present application describes deuterium-enriched BMS-690514, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076035 - Deuterium-enriched paliperidone: The present application describes deuterium-enriched peliperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076036 - Deuterium-enriched risperidone: The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076037 - Bicyclic pyrimidine kinase inhibitors: e

20090076038 - Deuterium-enriched entecavir: The present application describes deuterium-enriched entecavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076041 - Acyclic nucleoside derivatives: e

20090076039 - Deuterium-enriched valacyclovir: The present application describes deuterium-enriched valacyclovir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076040 - Deuterium-enriched valganciclovir: The present application describes deuterium-enriched valganciclovir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076043 - Deuterium-enriched alfuzosin: The present application describes deuterium-enriched alfuzosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076044 - Vegfr inhibitors containing a zinc binding moiety: The present invention relates to VEGFR inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20090076042 - Deuterium-enriched erlotinib: The present application describes deuterium-enriched erlotinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076045 - Non-nucleoside reverse transcriptase inhibitors: Compounds of formula I, wherein R1, X1, X2 and A, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090076047 - 2-substituted hydroxylaminopyrimidine, method for the production and the use thereof in the form of pesticides: m

20090076046 - Compounds modulating c-fms and/or c-kit activity and uses therefor: Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.... Agent: Foley & Lardner LLP

20090076048 - Deuterium-enriched xaliproden: The present application describes deuterium-enriched xaliproden, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076049 - Novel spiro [imidazolidine-4, 3' -indole] 2, 2', 5' (1h) triones for treatment of conditions associated with vanilloid receptor 1: The present invention relates to new compounds of formula (I), wherein R1 to R9 and X are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090076050 - Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: A method for treating a subject suffering cancer, comprising administering an effective amount of berberine or its acid or ester derivates to the subject in need of such treatment, and radiating the cancer of the subject.... Agent: Wpat, PC Intellectual Property Attorneys

20090076051 - Deuterium-enriched methylnaltrexone: The present application describes deuterium-enriched methylnatrexone bromide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076052 - Deuterium-enriched nalmefene: The present application describes deuterium-enriched nalmefene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076053 - Methods and compositions for treating pain: Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular,... Agent: Wilson Sonsini Goodrich & Rosati

20090076056 - Deuterium-enriched topotecan: The present application describes deuterium-enriched topotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076055 - Deuterium-enriched vinflunine: The present application describes deuterium-enriched vinflunine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076054 - Test method for endotoxin: An object of the present invention is to provide a method capable of detecting and quantifying endotoxin in a sample in which endotoxin derived from gram-negative bacteria cannot be accurately detected or quantified by the method described in Commentary of the Japanese Pharmacopoeia Fourteenth Edition, Hirokawa Publishing Co. 2001 B-63.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090076057 - Deuterium-enriched dutasteride: The present application describes deuterium-enriched dutasteride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076058 - Deuterium-enriched finasteride: The present application describes deuterium-enriched finasteride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076059 - Deuterium-enriched dianicline: The present application describes deuterium-enriched dianicline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076060 - Deuterium-enriched temsirolimus: The present application describes deuterium-enriched temsirolimus, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076063 - Carboxamide compound and use of the same: e

20090076064 - Compounds: Disclosed are compounds of Formula (I) wherein G, R2, A, D and E are as described in the specification, or pharmaceutically-acceptable salts, or in vivo-hydrolysable precursors thereof. Also disclosed herein is at least one method of making, at least one pharmaceutical composition containing, and at least one method for using... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090076061 - Muscarinic acetycholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090076062 - Organic compounds: and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting... Agent: Novartis Corporate Intellectual Property

20090076065 - Deuterium-enriched mk-0812: The present application describes deuterium-enriched MK-0812, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076066 - Deuterium-enriched zolpidem: The present application describes deuterium-enriched zolpidem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076067 - Pharmaceutical composition comprising azarhodacyanine compound as active ingredient: The object of the invention is to provide pharmaceutical composition that can be used as a therapeutic and/or prophylactic agent. Particularly, the pharmaceutical composition of the invention has significant therapeutic effect and survival benefit for the disease caused by parasitic protozoa, and selective toxicity against the causative protozoa. The pharmaceutical... Agent: Dla Piper LLP (us) Attn: Patent Group

20090076068 - Imidazopyridin-2-one derivatives as inhibitors of lipases and phospholipases: The present invention relates to imidazopyridin-2-one derivatives of the formula I with the definitions specified in the description, to their pharmaceutically usable salts and to their use as medicaments.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090076069 - Deuterium-enriched apixaban: The present application describes deuterium-enriched apixaban, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076070 - Hetero compound: [Means for Solving] Since the compound of the invention has an S1P1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ,... Agent: Fitzpatrick Cella Harper & Scinto

20090076071 - Deuterium-enriched retapamulin: The present application describes deuterium-enriched retapamulin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076072 - Deuterium-enriched tafenoquine: The present application describes deuterium-enriched tafenoquine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076074 - Quinoline derivatives: or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use... Agent: Morgan Lewis & Bockius LLP

20090076075 - Quinoline derivatives: or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in... Agent: Morgan Lewis & Bockius LLP

20090076073 - Therapeutic amides: wherein X, Y, and Z are as defined in the specification. The compounds are effective anti-tumor agents. The invention also provides pharmaceutical compositions comprising a compound of the above formula or a salt thereof, intermediates useful for preparing a compound of the above formula, and therapeutic methods comprising administering a... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20090076076 - Inhibitors of cysteine proteases and methods of use thereof: The present invention relates to semicarbazone or thiosemicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090076077 - Methods and compositions for selectin inhibition: e

20090076078 - New compounds 966:

20090076080 - Deuterium-enriched fexofenadine: The present application describes deuterium-enriched fexofenadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076079 - Deuterium-enriched methylphenidate: The present application describes deuterium-enriched methylphenidate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076081 - Piperidine derivatives as nk3 antagonists: e

20090076082 - Deuterium-enriched alvimopan: The present application describes deuterium-enriched alvimopan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076083 - Deuterium-enriched saredutant: The present application describes deuterium-enriched saredutant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076085 - Deuterium-enriched nicraven: The present application describes deuterium-enriched nicraven, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076084 - Wound and mucous membrane disinfectant: Aqueous wound and mucous membrane disinfectant containing a) octenidine dihydrochloride, and b) one or more active ingredients selected from the group ethanol, 1-propanol, 2-propanol, undecylene amidopropyl trimonium methosulfate, 3-(4-chlorophenoxy)-1,2-propanediol and/or sodium hydroxymethylglycinate and c) glycerin and/or 1,2-diols having 3 to 10 carbon atoms, and d) optionally surfactants, emulsifiers, solubilisers, pH... Agent: Greenblum & Bernstein, P.L.C

20090076086 - Substituted nicotinamide compounds and uses thereof: u

20090076087 - Deuterium-enriched etoricoxib: The present application describes deuterium-enriched etoricoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076088 - Thrombin receptor antagonists: e

20090076089 - Deuterium-enriched pantoprazole: The present application describes deuterium-enriched pantoprazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076091 - Indazole-heteroaryl derivatives: The invention relates to novel indazole derivatives as cited in claim 1, which are inhibitors of CHK1, CHK2 and SGK kinases and can be used to treat cancer and other diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20090076092 - Method for disrupting reproductive performance of arthropods: Disclosed is a method for disrupting reproductive performance of an adult arthropod pest comprising contacting the adult arthropod pest or its environment with a sub-lethal, reproduction-disruptive amount of a carboxamide arthropodicide, its N-oxide, or a salt thereof.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090076090 - Treated expanded polystyrene foam: Expanded polystyrene coated with at least one organic pesticide, methods for making expanded polystyrene coated with at least one organic pesticide, and molded articles made from expanded polystyrene coated with at least one organic pesticide is provided herein.... Agent: Lanxess Corporation

20090076093 - Deuterium-enriched rosiglitazone: The present application describes deuterium-enriched rosiglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076094 - Novel antibacterial compounds: of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090076095 - Deuterium-enriched nicorandil: The present application describes deuterium-enriched nicorandil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076096 - 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides: e

20090076097 - Deuterium-enriched atazanavir: The present application describes deuterium-enriched atazanavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076100 - Deuterium-enriched gsk625433: The present application describes deuterium-enriched GSK625433, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076099 - Deuterium-enriched ixabepilone: The present application describes deuterium-enriched ixabepilone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076098 - Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones: The invention provides methods, kits and compounds for determining the potential responsiveness of a subject suffering from a pathological disorder, including non-small cell lung cancer (NSCLC), to treatment with an epothilone by analyzing the gene expression profile and/or certain molecular markers in a sample obtained from said subject. The invention... Agent: Millen, White, Zelano & Branigan, P.C.

20090076101 - Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory... Agent: Merck And Co., Inc

20090076102 - Deuterium-enriched muraglitazar: The present application describes deuterium-enriched muraglitazar, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076103 - Stem cell differentiating agents and uses therefor: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.... Agent: Fulbright & Jaworski L.L.P.

20090076104 - Deuterium-enriched losartan: The present application describes deuterium-enriched losartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076105 - Preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemia reperfusion in stroke: The present invention provides a preventive or therapeutic agent for cerebral ischemic injury or cerebral ischemic reperfusion injury in stroke such as cerebral infarction and cerebral hemorrhage which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for along period. The present... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20090076106 - 2-(phenylamino) benzimidazole derivatives and their use as modulators of small- conductance calcuim-activated potassium channels: e

20090076107 - Deuterium-enriched odansetron: The present application describes deuterium-enriched ondansetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076108 - Method for treating obesity: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition... Agent: Knobbe Martens Olson & Bear LLP

20090076109 - Pharmaceutical composition for external use: e

20090076110 - Amino acid compounds: An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Agmatine, Arginine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine.... Agent: Booth Udall, PLC

20090076111 - Methods for improving glycemic control in humans: The present invention is directed to methods for improving glycemic control in humans and animals comprising the step of administering a composition comprising an amino acid content including 4-hydroxyisoleucine in an amount between about 60% and about 70% of a total weight of the amino acid content, together with one... Agent: Pate Pierce & Baird

20090076112 - Deuterium-enriched eltrombopag: The present application describes deuterium-enriched eltrombopag, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076113 - Biphenylcarboxamides for controlling micro-organisms: e

20090076114 - Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes: The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.... Agent: Seed Intellectual Property Law Group PLLC

20090076115 - Photosensitizers for targeted photodynamic therapy: The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.... Agent: Ewards Angell Palmer & Dodge LLP

20090076116 - Deuterium-enriched carvediolo: The present application describes deuterium-enriched carvedilol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076117 - Deuterium-enriched laropiprant: The present application describes deuterium-enriched laropiprant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076119 - Deuterium-enriched ramipril: The present application describes deuterium-enriched ramipril, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076118 - Deuterium-enriched saxagliptin: The present application describes deuterium-enriched saxagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076120 - Crystal of aminopyrrolidine derivative and production method thereof: Two crystal forms of (R)-3-[2-(2-amino-5-trifluoromethoxybenzamido)acetamido]-1-(6-methylindol-3-ylmethyl)pyrrolidine which exhibit specific X-ray powder diffraction patterns or infrared absorption spectra, amorphous form thereof, a pharmaceutical composition containing the crystal or amorphous form as an active ingredient, as well as methods for preparing them are provided.... Agent: Sughrue Mion, PLLC

20090076121 - Deuterium-enriched sumatriptan: The present application describes deuterium-enriched sumatriptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076123 - Medical compositions for intravesical treatment of bladder cancer: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during... Agent: K&l Gates LLP

20090076122 - Parp modulators and treatment of cancer: In particular, substituted benzopyrones and substituted indoles and their pharmaceutical compositions containing such compounds that modulate the activity of PARP-1, are described. The invention is also directed to the composition of matter, kits and methods for their therapeutic and/or prophylactic use in treating diseases and disorders described herein, by administering... Agent: Wilson Sonsini Goodrich & Rosati

20090076124 - Deuterium-enriched ropinirole: The present application describes deuterium-enriched ropinirole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076126 - Deuterium-enriched enalapril: The present application describes deuterium-enriched alendronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076125 - Deuterium-enriched glimepiride: The present application describes deuterium-enriched glimepiride, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076127 - Deuterium-enriched larotaxel: The present application describes deuterium-enriched larotaxel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076128 - Deuterium-enriched topiramate: The present application describes deuterium-enriched topiramate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076131 - Anti-cancer and anti-inflammatory effects of annurca apple extracts and compositions purified therefrom: The present invention includes compositions and methods for modulating cell proliferation using a pharmaceutical effective amount of an isolated and purified polyphenolic composition having one or more polyphenolic compounds extracted from one or more plant tissues, specifically from one or more tissues of the Annurca apple.... Agent: Chalker Flores, LLP

20090076132 - Antiviral compositions and methods of treatment: A composition and method of treatment of viruses in the Poxviridae family of infections and their associated symptoms using a tree extract out of which the majority (>90%) of dry mass are hydrolyzing flavonoids. Other extract components include taspine, dihydrobenzofuran lignan, phenols, steroids; and diterpenoids. The composition, flavokine, has been... Agent: Williams Mullen

20090076130 - Compounds for the inhibition of histone deacetylase: and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an... Agent: Wpat, PC Intellectual Property Attorneys

20090076129 - Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, alpha-amylase and alpha-glucosidase activity in mammals: The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of C. quadrangularis to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals. By example and not by way of limitation, embodiments of the present disclosure, a composition... Agent: Greenberg Traurig LLP (la)

20090076133 - Deuterium-enriched zanamivir: The present application describes deuterium-enriched zanamivir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076134 - Deuterium-enriched simvastatin: The present application describes deuterium-enriched simvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076135 - Deuterium-enriched hydromorphone: The present application describes deuterium-enriched hydromorphone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076136 - Therapeutic agent: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed, an agent for enhancement of glucose uptake into a cell, and an agent for inducing differentiation... Agent: Birch Stewart Kolasch & Birch

20090076138 - Deuterium-enriched darunavir: The present application describes deuterium-enriched darunavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076137 - Deuterium-enriched dronedarone: The present application describes deuterium-enriched dronedarone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076139 - Deuterium-enriched oxalplatin: The present application describes deuterium-enriched oxaliplatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076140 - Pharmaceutical compositions containing sulphonic acid derivatives: A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10OR11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH—CO—R12, where R12 is C1-C6 alkyl or C6-C10... Agent: Sheridan Ross PC

20090076141 - Use of propofol prodrugs for treating neuropathic pain: Methods of treating alcohol neuropathic pain in a patient comprising orally administering a therapeutically effective amount of a propofol prodrug having high oral bioavailability are disclosed.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090076142 - Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds: The invention provides methods of synthesizing the purified enantiomers of oleocanthal. The invention further provides methods of using oleocanthals in various formulations including, food additives; pharmaceuticals; cosmetics; animal repellants; and discovery tools for mammalian irritation receptor genes, gene products, alleles, splice variants, alternate transcripts and the like.... Agent: Woodcock Washburn LLP

20090076143 - Compositions and methods for treating inflammation and inflammation-related disorders by plectranthus amboinicus extracts: The crude extract of Plectranthus Amboinicus (PA) has anti-inflammatory effects and can inhibit AP-1 binding in vitro. The incubation with PA crude extract resulted in significant inhibition of the LPS-induced expression of IL-6, IL-12, MCP-1, and RANTES in HUVEC cells. After the crude extract was further fractionated using preparative HPLC,... Agent: Greenberg Traurig LLP (la)

20090076144 - Deuterium-enriched bazedoxifene: The present application describes deuterium-enriched bazedoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076145 - Deuterium-enriched amibegron: The present application describes deuterium-enriched amibegron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076147 - Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use: Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders,... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090076146 - Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome: The use of acetyl L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicament and/or dietetic product for the treatment of fibromyalgic syndrome.... Agent: Lucas & Mercanti, LLP

20090076148 - Deuterium-enriched pravastatin: The present application describes deuterium-enriched pravastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076149 - Production method of oil or fat containing polyunsaturated fatty acid-containing triglyceride: The present invention relates to a production method of an oil containing triglyceride in which medium chain fatty acids are bound to the 1- and 3-positions of the triglyceride and polyunsaturated fatty acid is bound to the 2 position by allowing lipase, which specifically acts on ester bonds at the... Agent: Drinker Biddle & Reath (dc)

20090076150 - Deuterium-enriched bromfenac: The present application describes deuterium-enriched bromfenac, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076151 - Method for stimulating weight loss and/or for lowering triglycerides in patients: Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.... Agent: Morrison & Foerster LLP

20090076152 - Novel compounds active as muscarinic receptor antagonists: m

20090076153 - Deuterium-enriched tigecycline: The present application describes deuterium-enriched tigecycline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076154 - Deuterium-enriched vorinostat: The present application describes deuterium-enriched vorinostat, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076157 - Deuterium-enriched senicapoc: The present application describes deuterium-enriched senicapoc, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076155 - Modulators (inhibitors/activators) of histone acetyltransferases: The invention provides the use of certain benzoic acid and benzamide compounds as modulators of enzymes histone acetyltransferases, which are involved in gene expression and cancer and also use of such compounds in the treatment of diseases due to defects in gene regulation predominantly cancer.... Agent: Intellectual Property Dept. Dewitt Ross & Stevens Sc

20090076156 - Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders: The present invention relates to the use of a noradrenergic agonist for the treatment of a patient with a cognitive disorder resulting from acquired brain damage, wherein the cognitive disorder includes, for example, hemi-spatial neglect.... Agent: Frost Brown Todd, LLC

20090076158 - Deuterium-enriched bicalutamide: The present application describes deuterium-enriched bicalutamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076159 - Deuterium-enriched eplivanserin: The present application describes deuterium-enriched eplivanserin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076160 - Use of r (+) -n-propargyl-1-aminoindan to treat or prevent hearing loss: A method of treating or inhibiting hearing loss in a mammalian subject, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof effective to treat or inhibit the hearing loss in the subject.... Agent: Cooper & Dunham, LLP

20090076161 - Deuterium-enriched bupropion: The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076162 - Deuterium-enriched desvenlafaxine: The present application describes deuterium-enriched desvenlafaxine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076163 - Deuterium-enriched dapoxetine: The present application describes deuterium-enriched dapoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076164 - Deuterium-enriched tapentadol: The present application describes deuterium-enriched tapentadol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076165 - Deuterium-enriched memantine: The present application describes deuterium-enriched memantine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076167 - Deuterium-enriched tramiprosate: The present application describes deuterium-enriched tramiprosate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090076166 - Enterically coated cystamine, cysteamine and derivatives thereof: 8 The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090076168 - Amine-based and imine-based polymers, uses and preparation thereof: The present invention relates to a modified polysaccharide prepared from the reaction between a polysaccharide comprising a plurality of monosaccharide subunits having at least one primary amino group, and an hydrophobic aldehyde. The aldehyde and the amino group form together an imine or amine group. The process for preparation and... Agent: Bereskin And Parr

20090076169 - Differential evaporation potentiated disinfectant system: Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms.... Agent: Cr Miles, P.C. Craig R. Miles

20090076170 - Stable organic peroxide compositions: Benzoyl peroxide compositions are stabilized against decomposition by the use of antioxidants, resulting in increased shelf life of products made using the compositions. Treatment of truncal acne vulgaris with a combination of actives, namely benzoyl peroxide and salicylic acid, is provided via regimens that include applying such benzoyl peroxide compositions... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090076171 - Metallofullerols and their applications for preparation of medicine for inhibition of tumor growth: This invention provides a composition of polyhydroxylated metallofullerene compound and its application in the preparation of antitumor pharmaceutical. In one embodiment, metallofullerol comprising the formula, M@C2m(OH)x, wherein M is selected from rare earth elements such as La or Gd; m is carbon atoms of 41 or 30; x is a... Agent: Staas & Halsey LLP

20090076172 - Prolonged deactivation: A method of obtaining a prolonged reduction in the allergen loading of an allergen-contaminated inanimate substrate comprises dispersing into an airspace at which the substrate is located an allergen-reducing amount of an allergen-deactivating compound. Preferably the dispersal of the compound into the airspace is as a vapour and aided by... Agent: Norris, Mclaughlin & Marcus

20090076173 - Delivery system for a hygienic agent: A delivery system for a hygienic agent according to the present invention includes an agent in a viscous paste and/or semi-solid gel form, which includes a skin benefiting composition containing cleansing and/or positive skin sensory elements. The system is configured to deliver the skin benefiting composition to the whole body... Agent: The Dial Corporation

20090076174 - Control release of biologically active compounds from multi-armed oligomers: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the... Agent: Feldmangale, P.A.

20090076175 - Polyamide-polyether block copolymer: Copolymers having linked internal polyether blocks and internal polyamide blocks have advantageous physical properties and solvent-gelling abilities. The copolymer may be prepared from a reaction mixture that contains 1,4-cyclohexane dicarboxylic acid (CHDA) and poly(alkyleneoxy) diamine (PAODA). Optionally, the reaction mixture contains no monofunctional compound reactive with either amine or carboxylic... Agent: Arizona Chemical Company C/o Bo Segers

20090076176 - Prodrugs activated by plasmin and their use in cancer chemotherapy: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20090076177 - Tamper resistant lipid-based oral dosage form for opioid agonists: A tamper resistant drug delivery system made of at least one lipid, at least one gelling agent and at least one drug active, such as oxycodone, where the system gels rapidly in the presence of water or a solution containing water, and the drug active releases into the digestive system,... Agent: Greensfelder Hemker & Gale PC

  
03/12/2009 > patent applications in patent subcategories. listing by industry category

20090069213 - Compositions for improving the health and appearance of skin: Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health... Agent: Townsend And Townsend And Crew, LLP

20090069214 - Modulator of metabolism processes and method of its receiving: A modulator of metabolic processes and method of manufacturing same is provided. The invention may have applicability in at least the fields of medicine, veterinary medicine, medical industry, and agriculture. The essence of invention is a chemically modified biopolymer with a polypeptide chain as an exogenous modulator of metabolic and... Agent: Beem Patent Law Firm

20090069215 - Acylated single chain insulin: The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in at least one of the positions B20, B21 or B22... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090069216 - Single-chain insulin analogues and pharmaceutical formulations thereof: The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090069217 - Nutrient composition: Provided is a nutrient composition for promoting collagen production, which contains vitamin C, an iron preparation, and collagen as active ingredients, promotes collagen production in a living body such as skin or bone, prevents or treats skin aging or bone and joint diseases, and is an iron preparation-containing composition having... Agent: Young & Thompson

20090069219 - Deuterium-enriched telavancin: The present application describes deuterium-enriched telavancin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069218 - Pharmaceutical compositions comprising casein derived peptides and methods of use thereof: The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare.... Agent: Fennemore Craig

20090069220 - Dna-binding polyamide drug conjugates: in which W and W′ are independently a DNA intercalator or terminal subunit, V and V′ are independently a DNA intercalator, X and X′ are independently a DNA alkylator, B and B′ are the same or different and each is a heteroaromatic residue that is attached to the N-terminus of... Agent: Leydig, Voit & Mayer, Ltd.

20090069222 - Compounds useful as modulators of the proteasome activity: The present invention relates to the use of compounds of the following general formula (I): wherein no is 0 or 1, and when no is 1, X=CH2 or X=NCH2C6H5; R1 is OH, or a OR10 group, or a group of formula NH—(CH2)n1—R11; R2 is H, or an alkyl group, or... Agent: Young & Thompson

20090069224 - Linear and cyclic melanocortin receptor-specific peptidomimetics: e

20090069223 - Method for treatment of vascular hyperpermeability: A method for the treatment of apoptotic-induced vascular hyperpermeability is disclosed herein. Administration of various compounds including intrinsic mitochondrial regulatory proteins, certain pharmaceuticals, antioxidants and endothelial growth factors alone or in combination results in elevating the threshold for apoptosis in patients with hemorrhagic shock. Elevating the threshold for apoptosis in... Agent: Strasburger & Price, LLP

20090069221 - Somatostatin analogue formulations: The present invention relates to pre-formulations of a low viscosity mixture containing: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one somatostatin analogue; wherein the pre-formulation forms, or is capable of forming, at least one... Agent: Nixon Peabody, LLP

20090069225 - Somatostatin analogues: The invention provides cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.... Agent: Novartis Corporate Intellectual Property

20090069238 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Dean G. Stathakis Allergan, Inc. -t2-7h

20090069233 - Agonist peptides of basic fibroblast growth factor (bfgf) and the method of reduction of wrinkles on skin, darkening of hair and acceleration of wound healing: The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected... Agent: The Webb Law Firm, P.C.

20090069234 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.... Agent: Morgan Lewis & Bockius LLP

20090069231 - Compositions and methods for treating diabetic eye disease: The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive retinal vascularisation and vascular permeability, e.g., diabetic retinopathy and diabetic macular edema.... Agent: Fish & Richardson PC

20090069241 - Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments: The invention provides PEDF peptides which retain the biological activity of full-length PEDF. Fusion proteins comprising a PEDF peptide are also provided. The invention further provides a codon-optimized PEDF coding sequence and method of expressing it in bacteria. Compositions, methods of use and kits are also provided.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090069230 - Gdnf-derived peptides: Compositions that include peptides derived from glial-derived neurotrophic factor (GDNF) (e.g., substantially pure polypeptides comprising a fragment of a GDNF precursor protein) and biologically active variants thereof are provided. The compositions can include one or more types of peptides and can include other substances (e.g., pharmaceutically acceptable carriers or diluents... Agent: Fish & Richardson P.C.

20090069232 - Glycosylation of molecules: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.... Agent: Fish & Richardson P.C.

20090069235 - Igf-1 fusion polypeptides and therapeutic uses thereof: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1... Agent: Regeneron Pharmaceuticals, Inc

20090069240 - Method of preventing and treating endocrine system disturbances: The inventive medicinal agent for preventing and treating endocrine system disturbances appears as a powder prepared from ossified reindeer horns and contains 120 IU/g of luteinizing hormone, and 54 IU/g of follicle-stimulating hormone, 2,1 IU/g of prolactin, 203 pg/g of adrenocorticotropic hormone, 2,2 ng of somatotropic hormone, thyroidal hormones including... Agent: Smith Hopen, Pa

20090069237 - Methods and compositions for treating conditions: The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically... Agent: Wilson Sonsini Goodrich & Rosati

20090069229 - Plant-made west nile virus (wnv) vaccines, vectors and plant codon optimized sequences: The subject application provides various compositions of matter directed to West Nile virus (WNV) polypeptides and fragments thereof and polynucleotides, vectors and transformed host cells that encode, direct the expression of, or produce WNV polypeptides as set forth herein. Methods of using the polypeptides and polynucleotides for the production of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090069236 - Process for the preparation of hypoallergenic major birch pollen allergen rbet v 1: The invention relates to a process for the preparation of hypoallergenic major birch pollen allergens by means of one or more chromatographic purification steps using essentially unbuffered aqueous bases as eluent and subsequent neutralisation. The hypoallergenic major birch pollen allergens are distinguished by a lack of, but at least by... Agent: Millen, White, Zelano & Branigan, P.C.

20090069228 - Screening method: The present invention provides compounds or their salts that promote or inhibit the activities of a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, compounds or their salts that promote or inhibit the activities of a gene for said... Agent: Edwards Angell Palmer & Dodge LLP

20090069226 - Transmucosal delivery of peptides and proteins: Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090069239 - Use of iridoptin to induce toxicity in insects: Improved methods and compounds to control insects, involving a biological control method to induce toxicity in targeted insects using iridoptin. The present invention induces high levels of apoptosis and inhibition of host protein synthesis in insect cells. It is the first viral toxin against non-lepidopteran insects and is distinct from... Agent: Kammer Browning PLLC

20090069242 - Therapeutically active alpha msh analogues: The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical... Agent: Roberts Mlotkowski Safran & Cole, P.C. Intellectual Property Department

20090069243 - Natriuretic activities: This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.... Agent: Fish & Richardson P.C.

20090069245 - Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof: The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20090069244 - Mutants of lactoferrin: The invention relates to field of biochemistry, molecular biology as well as medicinal chemistry. More in specific, the invention relates to polypeptides derived from human lactoferrin and their use in therapeutic or prophylactic treatment. The invention provides a polypeptide comprising a mutant of the amino acid sequence RRRRSVQWC (SEQ ID... Agent: Trask Britt

20090069246 - Methods for promoting hematopoietic and mesenchymal cell proliferation and differentiation: The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090069247 - Use of tight junction antagonists to treat inflammatory bowel disease: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090069248 - Substrate peptide sequences for plague plasminogen activator and uses thereof: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation... Agent: Benjamin Aaron Adler Adler & Associates

20090069249 - Methods for reducing oxidative stress in a cell with a sulfhydryl protected clutathione prodrug: The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090069250 - Inhibitors of histone deacetylase: The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful... Agent: Merck And Co., Inc

20090069251 - Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases: The present invention relates to methods and compositions for the treatment and/or prevention of neuropathological and/or neurodegenerative diseases. In particular, the invention delivers novel uses of inhibitors of Urokinase-type Plasminogen activator in the treatment of amyotrophic lateral sclerosis.... Agent: Mcdermott Will & Emery LLP

20090069252 - C-glycoside derivatives and salts thereof: The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent... Agent: Sughrue Mion, PLLC

20090069253 - Whitening cosmetic composition containing arbutin nanoparticles: The present invention provides a whitening cosmetic composition containing arbutin at a high concentration, whereby an improved whitening effect can be attained. In the arbutin-containing whitening cosmetic composition, arbutin is in the form of nanoparticles obtained through a nanoparticle-forming treatment of an aqueous arbutin dispersion. The composition preferably contains arbutin... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090069254 - Agent for inhibiting visceral fat accumulation: To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity considered to be a main factor of metabolic syndrome, there is provided an agent or a food or drink, including as an active ingredient 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol, an organic solvent extract, a hot water... Agent: Knobbe Martens Olson & Bear LLP

20090069255 - Deuterium-enriched clarithromycin: The present application describes deuterium-enriched clarithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069263 - 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof: Oligonucleotides comprising one or more 4′-thioarabinonucleotides are described, as well as uses thereof for applications such as antisense- and RNAi-based gene silencing. 4′-thioarabinose-based phosphoramidite and H-phosphonate compounds are also described, as well as uses thereof for the synthesis of oligonucleotides comprising one or more 4′-thioarabinonucleotides.... Agent: Goudreau Gage Dubuc

20090069262 - Cationic oligonucleotides, automated methods for preparing same and their uses: The invention relates to oligonucleotide-oligocation molecules AiBjH that can be synthetized via automated phosphoramidite chemistry having oligonucleotides moieties Ai and oligocations moieties Bj, wherein. Ai is an i-mer oligonucleotide residue, with i=5 to 50, where nucleotide A is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups... Agent: Nixon & Vanderhye, PC

20090069256 - Enhancing protein expression: Modified polynucleotide compositions providing enhanced gene expression and methods for preparing said compositions are disclosed. Methods of using the compositions, such as in screening assays, diagnostic tools, kits, etc. and for prevention and/or treatment of diseases and disorders are also disclosed.... Agent: Hunton & Williams LLP Intellectual Property Department

20090069261 - Gene therapy for spinal cord disorders: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector... Agent: Genzyme Corporation Legal Department

20090069260 - Method for producing a nucleic-acid-containing complex preparation: The present invention relates to a method of preparing a nucleic-acid-containing complex formulation which can be sterilized by filtration and administered intravenously to a human, and can retain stability of polynucleotides included in the nucleic-acid-containing complex formulation. The invention also relates to a method of preparing a nucleic-acid-containing complex formulation,... Agent: Darby & Darby P.C.

20090069257 - Method of achieving persistent transgene expression: Non-inflammatory vector compositions are provided that are suitable for repeated transgene delivery and that result in persistent transgene expression. The compositions are non-inflammatory, the present compositions are suitable for readministration and do not induce expression-limiting immune or inflammatory responses. Thus, these compositions are useful in methods of repeated administration to... Agent: Ropes & Gray LLP

20090069266 - Methods and compositions for nucleic acid transfer into cells: The present invention provides compositions and methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and/or... Agent: Casimir Jones, S.c.

20090069258 - Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof: DNA encoding a recombinant antibody molecule end-specific for an amyloid-beta peptide, pharmaceutical compositions thereof, and a method for preventing or inhibiting progression of Alzheimer's Disease by introducing such a DNA molecule into brain cells to express the recombinant antibody molecule and prevent the accumulation of amyloid-beta peptides in the cerebrospinal... Agent: Darby & Darby P.C.

20090069265 - Sirna targeting inner centromere protein antigens (incenp): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090069264 - Toxoplasma gondii nucleic acid molecules: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are... Agent: Heska Corporation Legal Department

20090069259 - Treatment of neuropathic pain with zinc finger proteins: A variety of zinc finger proteins (ZFPs) and methods utilizing such proteins are provided for use in treating neuropathic pain. ZFPs that bind to a target site in genes that are aberrantly expressed in subjects having neuropathic pain are described. In addition, ZFPs that bind to a target site in... Agent: Townsend And Townsend And Crew, LLP

20090069267 - Central administration of stable formulations of therapeutic agents for cns conditions: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing... Agent: Morrison & Foerster LLP

20090069268 - Novel phosphoramidate compounds and methods of use: This invention provides compounds, compositions and methods for treating cancer, infectious disease, an autoimmune disorder or an inflammatory condition. Therapeutic compounds useful in the methods of this invention are 5′-phosphoramidatyl, 1,5-substituted pyrimidine compounds, derivatives, analogs and pharmaceutically acceptable salts thereof... Agent: Foley & Lardner LLP

20090069269 - Oral composition containing difructose anhydride: An oral composition for increasing equol production by inner-intestinal bacteria, wherein such composition contains difructose anhydride as an active ingredient to activate the equol production function of inner-intestinal bacteria.... Agent: Knobbe Martens Olson & Bear LLP

20090069270 - Methods for diluting water-stabilized antimicrobial organosilane compositions: The present invention relates to methods for diluting water-stable organosilane compositions comprising an organosilane, optionally having a non-hydrolyzable organic group, but having one or more hydrolyzable groups, and an acidified stabilizing solution prepared from at least one acid, and at least one cationic surfactant, preferably at least one quaternary ammonium... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090069271 - Wood treatment: A method of introducing boron as a boron ester into timber via a non-aqueous liquid medium. The borate ester may have the formula I: (R1O)(R2O)(R3O)B where R1 may be a C3-C20 alkyl or alkenyl group, R2 may be a C3-C20 alkyl or alkenyl group and R3 may be a C3-C20... Agent: Brooks Kushman P.C.

20090069272 - Composition for treating bone disorders: Disclosed is a new composition of matter, substantially enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid, methods of preparing this new composition of matter, a pharmaceutical composition comprising the new composition, and administration of the composition in methods of treating bone disorders such as osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090069227 - Use of hmgb1 to promote stem cell migration and/or proliferation: It is described a method to promote stem cell migration and/or proliferation in cell culture or in vivo comprising the step of exposing such cells to an effective amount of the HMGB1 protein or its active fragment.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090069273 - Phosphorylated pyrone analogs and methods: The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and... Agent: Wilson Sonsini Goodrich & Rosati

20090069274 - Interferon-like protein zcyto21: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090069275 - Low flush niacin formulation: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.... Agent: Paul D. Yasger Abbott Laboratories

20090069276 - Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof: The present invention relates to a method for preventing, treating or ameliorating pulmonary disorders in a patient receiving a chemotherapeutic or radiotherapeutic agent or treatment comprising administering to the patient a pharmaceutical composition comprising an effective amount of active vitamin D compound or a mimic thereof. According to the invention,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090069277 - Compounds and compositions for treating infection: Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.... Agent: Cooper & Dunham, LLP

20090069278 - Hormonally-timed dermatological preparations: This invention provides a dermatological preparation to improve skin cosmesis or conditioning by using different formulations in a sequence that suits the needs of the skin at different points of the hormonal cycle. In its simplest implementation, this would be a two-phase skin treatment, such as a cosmetic, lotion or... Agent: Chiaoyun Kuo Agent For Applicants

20090069279 - Invert emulsions containing dhea: Stable, recrystallization-resistant invert emulsions, suited, e.g., for preventing/treating the signs of chronological or actinic skin aging and for preventing/treating atrophy of the skin or mucous membranes, comprise a cosmetically/therapeutically effective amount of DHEA and/or chemical and/or biological precursor or derivative thereof, such invert emulsions also comprising a glycolic or hydroglycolic... Agent: Buchanan, Ingersoll & Rooney PC

20090069280 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Foley Hoag, LLP (w/ipx)

20090069281 - Ansamycin formulations and methods of use thereof: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock... Agent: Choate, Hall & Stewart LLP

20090069285 - Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity: 2-azetidinone derivatives and pharmaceutical compositions containing them. The compounds are useful in the treatment of hyperlipidemic conditions, atherosclerosis, Alzheimers' disease and cholesterol associated tumours.... Agent: Pepper Hamilton LLP

20090069286 - Deuterium-enriched aztreonam: The present application describes deuterium-enriched aztreonam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069287 - Substituted azacycloalkanes useful for treating cns conditions: The invention relates to substituted azacycloalkaπe compounds useful in treating conditions of the Central Nervous System (CNS); a pharmaceutical composition comprising same; a method of treating such conditions and of treating conditions in which inhibition of beta-secretase is indicated.... Agent: Pfizer Inc Steve T. Zelson

20090069288 - Novel therapeutic compounds: e

20090069282 - Alkyne compounds with mch antagonistic activity and medicaments comprising these compounds: wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090069283 - Potassium channel inhibitors: The present invention relates to pyridine substituted ethanol compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20090069284 - Substituted 3-alkyl and 3-alkenyl azetidine derivatives: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20090069289 - 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression: The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II:... Agent: Heslin Rothenberg Farley & Mesiti PC

20090069290 - Method for treating a demyelinating condition: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of... Agent: Amster, Rothstein & Ebenstein LLP

20090069292 - Liquid formulations: The present invention is directed to liquid formulations of the pharmaceutical compound 1 1-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as preparations, and pharmaceutical uses thereto.... Agent: Pepper Hamilton LLP

20090069291 - Salt forms: The present invention is directed to salts the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof.... Agent: Pepper Hamilton LLP

20090069293 - Succinoylamino benzodiazepines as inhibitors of ab protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20090069294 - Organic compounds: The present disclosure relates to XIAP inhibitor compounds of the formula I.... Agent: Novartis Corporate Intellectual Property

20090069295 - Deuterium-enriched conivaptan: The present application describes deuterium-enriched conivaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069296 - 1,2,4,5-tetrahydro-3h-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them: e

20090069297 - Aurora kinase modulators and method of use: wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase... Agent: Amgen Inc.

20090069298 - Pyrazolo[1,5-a]pyrimidine compounds: R00 is an alkyl group, Q1 is a single bond etc., Q2 is a single bond or an alkylene group, one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., one of R50 and R60 is a hydrogen atom... Agent: Birch Stewart Kolasch & Birch

20090069300 - Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.... Agent: Wyeth Patent Law Group

20090069299 - Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods: Pyrazolo[3,4-c]quinolines, pyrazolo[4,5-c]naphthyridines, and analogs thereof, eg., 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inhibiting cytokine biosynthesis in animals and in the therapeutic or prophylactic treatment of diseases by inhibiting cytokine biosynthesis are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090069301 - Acridine and quinoline derivatives as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Ropes & Gray LLP

20090069302 - Chemical compounds: The present invention relates generally to novel therapeutic compounds and AXOR 109 agonists, and processes for the manufacture and use of the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090069304 - Mmp-13 selective inhibitor: (R6 and R7 are each independently halogen, lower alkyl etc.; m and n are each independently 0, 1, or 2); R2 is a hydrogen atom, optionally substituted lower alkyl etc.; R3 is a hydrogen atom, optionally substituted lower alkyl etc.; R4 is a hydrogen atom; or R3 and R4 may... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090069303 - Phthalazinone derivatives: 6

20090069305 - Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor: The present invention relates to substituted nitrogen-containing heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using any of these derivatives and compositions for H4 receptor activity modulation and the treatment of states mediated by histamine H4 receptor activity.... Agent: Philip S. Johnson Johnson & Johnson

20090069306 - Process for producing highly pure midazolam and salts thereof: Provided is a process for producing highly pure midazolam and salts thereof, and a pharmaceutical composition containing the highly pure midazolam and/or a salt thereof.... Agent: Leydig Voit & Mayer, Ltd

20090069307 - Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions: The present invention relates to use of a pyridine compound of the following formula [I]: wherein R is a substituted pyridyl group having the following formula: R0 is a C1-6 alkoxy-C1-6 alkyl group, R1 and R2 are the same or different and a C1-6 alkoxy group, X is a group... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090069308 - Novel use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses: The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates... Agent: Birch Stewart Kolasch & Birch

20090069309 - Prostaglandin analogs: e

20090069311 - 5-aminoindole derivatives as h3 inverse agonists: wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090069310 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.... Agent: Hovey Williams LLP

20090069312 - Potassium channel inhibitors: The present invention relates to dipyridin-3-ylmethoxy compounds and derivatives thereof having the structure I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20090069313 - Novel mao-a inhibitors: The present invention provides a new medical use for the compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, as MAO-A inhibitors. Also included is a method for prophylaxis and treatment of mental disorders such as... Agent: Oliff & Berridge, PLC

20090069314 - Hydroxyalkyl substituted imidazoquinoline compounds and methods: Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of... Agent: Wolf Greenfield & Sacks, P.C.

20090069315 - Use of pyrazolo(1,5a)pyrimidin-7-yl amine derivatives in the treatment of neurological disorders: The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor... Agent: Novartis Corporate Intellectual Property

20090069316 - Novel quinoline derivatives: and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of... Agent: Pfizer Inc

20090069317 - Insecticidal methods using 3-amino-1,2-benzisothiazole derivatives: The invention relates to insecticidal methods using 3-amino-1,2-benzoisothiazole compounds of the formula (I) wherein the variables n and R1 to R6 are as defined in the description. The invention relates to methods of combating or controlling insects, arachnids or nematodes, to methods for protecting growing plants from attack or infestation... Agent: Brinks, Hofer, Gilson & Lione

20090069319 - Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system: The present invention relates to imidazopyridine analogs, methods of making imidazopyridine analogs, compositions comprising an imidazopyridine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of an imidazopyridine analog.... Agent: Wyeth Patent Law Group

20090069318 - Novel compounds: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090069320 - Substituted 4-amino-quinazoline compounds with metabotropic glutamate receptor regulating activity and uses thereof: v

20090069321 - Cyanomethyl substituted n-acyl tryptamines:

20090069323 - 11beta-hsdi inhibitors: wherein A, Y, Z1, Z2, R1 to R3 and X1 to X4 have the meaning as cited in the description and the claims. For example A is 4′-fluorobiphen-4-yl; Y is —S(O)2NH—; R1, R2 are H; X1, X2, X4 are CH; X3 is C—F; Z1 is ═O; and Z2-R3 is N(CH2CH3)2.... Agent: Birch Stewart Kolasch & Birch

20090069324 - Chemical inhibitors of bfl-1 and related methods: Compounds that bind to Bfl-1 as well as conjugates of such compounds are provided. Various embodiments additionally provide methods of using such compounds to identify additional anti-apoptotic Bfl-1 binding compounds. Methods of using such compounds to increase apoptosis in a cell are also provided.... Agent: Knobbe Martens Olson & Bear LLP

20090069322 - N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections: Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(═O) or formula C(═O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or except when Z is a radical of formula —N(OH)CH(═O), a hydroxy, halo or amino... Agent: Banner & Witcoff, Ltd.

20090069325 - Piperidine derivatives useful as modulators of chemokine receptor activity: m

20090069326 - Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula I: (I) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes,... Agent: Eli Lilly & Company

20090069328 - Alpha-alkyl substituted n-acyltryptophanols: e

20090069327 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bmx, b-RAF, c-RAF, c-SRC, KDR,... Agent: Genomics Institute Of The Novartis Research Foundation

20090069329 - Cannabinoid receptor antagonists/inverse agonists useful for treating obesity: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.... Agent: Vance Intellectual Property, PC

20090069330 - Substituted oxazole compounds with analgesic activity: e

20090069331 - Guanidine derivatives as inhibitors of ddah: Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disease whose pathology is... Agent: Fulbright & Jaworski, LLP

20090069332 - Novel pyridazine derivatives and medicines containing the same as effective ingredients: wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl, group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090069333 - Fungicides: This invention relates to novel derivatives of pyridopyrazines and pyridopyridazines, to processes for preparing them, to intermediate chemicals used in their manufacture, to compositions containing them and to methods of using them to combat fungi, especially fungal infections of plants. The fungicidal compounds have the general formula (1) wherein R,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090069334 - Pyridazine based alpha-helix mimetics: The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available building block, 6. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a “wet face” along one side and a hydrophobic face... Agent: The Scripps Research Institute

20090069335 - Guanidine-containing compounds useful as muscarinic receptor antagonists: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for... Agent: Theravance, Inc.

20090069336 - Pyrimidothiophene compounds: wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C═O)—, —(C═S)—, —SO2—, —C(═O)O—, —C(═O)NRA—, —C(═S)NRA—, —SO2NRA—, —NRAC(═O)—, —NRASO2—... Agent: Banner & Witcoff, Ltd.

20090069337 - 3' substituted compounds having 5-ht6 receptor affinity: e

20090069338 - Method for predicting skin sensitizing activity of compounds: Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090069339 - Deuterium-enriched ciprofloxacin: The present application describes deuterium-enriched ciprofloxacin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069340 - Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders: Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090069341 - Inhibitors of hsp90: The invention relates to the use of benzoimidazolone compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising benzoimidazolone compounds, novel benzoimidazolone compounds, and a process for the preparation of the novel benzoimidazolone compounds.... Agent: Novartis Corporate Intellectual Property

20090069342 - Kv1.5 potassium channel inhibitors: The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.... Agent: Wyeth Patent Law Group

20090069343 - Combination histamine h1r and h4r antagonist therapy for treating pruritus: Patients suffering from pruritus or itch may be effectively treated by administering a centrally acting histamine H1 receptor antagonist (e.g., diphenhydramine, triprolidine, hydroxyzine, pyrilamine, promethazine, or chlorpheniramine) and a histamine H4 receptor antagonist (e.g., 5-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone).... Agent: Philip S. Johnson Johnson & Johnson

20090069344 - Modulators of hcv replication: t

20090069345 - Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine: The present invention is related to ophthalmic formulations for the treatment of ocular ailments. More specifically, it is related to the pharmaceutical industry in the production of ophthalmic medication for the treatment of ocular hypertension. The advantage of the present invention over other state of the art treatments is that... Agent: Intellectual Property Law Group LLP

20090069346 - Solid herbicidal composition: To provide a solid herbicidal composition in which decomposition of the herbicidal active ingredient is suppressed, and favorable herbicidal activity is stably exhibited. A solid herbicidal composition comprising (1) 1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-trifluoromethyl-2-pyridylsulfonyl)urea or its salt and (2) at least one surfactant selected from the group consisting of a naphthalene sulfonate condensed with... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090069347 - 2-phenoxy pyrimidinone analogues: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edward Angell Palmer & Dodge, LLP

20090069348 - Use of inhibitors of the renin-angiotensin system: It has been found that an inhibitor of the renin-angiotensin system is useful for the treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency. In particular, it may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090069349 - Deuterium-enriched pemetrexed: The present application describes deuterium-enriched pemetrexed, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069350 - Pharmaceutical compositions and use thereof: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090069351 - Deuterium-enriched bosentan: The present application describes deuterium-enriched bosentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069352 - Deuterium-enriched clazosentan: The present application describes deuterium-enriched clazosentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069355 - Bicyclic pyrazolone cytokine inhibitors: The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090069353 - Deuterium-enriched ambrisentan: The present application describes deuterium-enriched ambrisentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069354 - Deuterium-enriched gemcitabine: The present application describes deuterium-enriched gemcitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069357 - Deuterium-enriched iclaprim: The present application describes deuterium-enriched iclaprim, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069360 - Organic compounds: The present invention relates to the discovery that certain compounds inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway, and is concerned with compositions which contain these compounds, and methods of using them... Agent: Carstens & Cahoon, LLP

20090069359 - Topical and transdermal treatments using urea formulation: Various medical conditions, some previously treated by injection or surgery, are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, vasodilators, botulinum toxin and minoxidil. Conditions as diverse as spider veins, erectile dysfunction, facial wrinkles, hair loss and baldness... Agent: Lawrence J. Shurupoff

20090069356 - Use of anilinopyrimidines in wood protection: The present invention relates to the use of the anilinopyrimidines pyrimethanil, cyprodinil and mepanipyrim for the protection of wood and wood materials against wood destroying and wood discolouring fungi.... Agent: Philip S. Johnson Johnson & Johnson

20090069358 - Use of ikappab-kinase inhibitors in pain therapy: The present invention relates to the use of IκB-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090069361 - Methods of treatment using (+)- isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2, 6-dimethyl-pyridine-3, 5-dicarboxylate: The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents.... Agent: Darby & Darby P.C.

20090069362 - Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors: The present invention is directed to novel spiro-benzo[C]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes,... Agent: Philip S. Johnson Johnson & Johnson

20090069363 - Therapeutic agent for constipation: (wherein R1 represents hydrogen, lower alkyl, cycloalkyl lower alkyl or the like; R2 and R3 independently represent hydrogen, hydroxy or the like; R4 is hydrogen, hydroxy or the like; R5 is hydrogen; R4 and R5 may optionally form —O— or the like; R6 represents hydrogen, lower alkyl or the like... Agent: Ip Group Of Dla Piper US LLP

20090069364 - Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof: Non-occlusive compositions for transdermal delivery of 5-alpha-reductase inhibitors, and more particularly finasteride or dutasteride or pharmaceutically acceptable salts or derivatives thereof, and methods of making same. The composition may, for example, be a gel suitable for transdermal or transmucosal applications. The compositions of the present invention typically include a mixture... Agent: Winston & Strawn LLP Patent Department

20090069365 - Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090069366 - Deuterium-enriched tacrolimus: The present application describes deuterium-enriched tacrolimus, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069367 - Methods for treatment of cancer: A method for treating or preventing cancer in a subject comprising administering a treatment effective amount of a chemotype 4 compound.... Agent: Jhk Law

20090069368 - Fgf-receptor agonist dimeric compounds: FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090069369 - Deuterium-enriched prasugrel: The present application describes deuterium-enriched prasugrel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069370 - Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.... Agent: Wyeth Patent Law Group

20090069371 - Isoquinoline compounds: Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as... Agent: Michael Best & Friedrich LLP

20090069372 - Antitumor agents: wherein Y is F or Br; or a pharmaceutically acceptable salt thereof. The compounds are effective antitumor agents. The invention also provides pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, therapeutic methods comprising administering a compound of... Agent: Schwegman, Lundberg & Woessner, P.A.

20090069373 - Quinoline acids: This invention relates generally to quinoline-based modulators of Liver X receptors (LXRs) and related methods.... Agent: Fish & Richardson P.C.

20090069374 - Novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.... Agent: Black Lowe & Graham PLLC

20090069375 - Deuterium-enriched miglustat: The present application describes deuterium-enriched miglustat, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069377 - Deuterium-enriched enzastaurin: The present application describes deuterium-enriched enzastaurin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069376 - Vla-4 antagonists: Substituted N—[N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration... Agent: Merck And Co., Inc

20090069378 - Deuterium-enriched donepezil: The present application describes deuterium-enriched donepezil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069379 - Deuterium-enriched lenalidomide: The present application describes deuterium-enriched lenalidomide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069380 - Deuterium-enriched aroxifene: The present application describes deuterium-enriched arzoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069381 - Deuterium-enriched raloxifene: The present application describes deuterium-enriched raloxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069382 - Bicyclic angiotensin ii agonists: wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS... Agent: Nixon & Vanderhye, PC

20090069383 - Thrombin receptor antagonists: e

20090069384 - Thienopyrroles useful in the treatment of inflammation: There is provided compounds of formula I: wherein the dotted lines, U5 V5 X1, Y R1, R2 and R4 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG... Agent: Morgan Lewis & Bockius LLP

20090069385 - Antidiabetic oxazolidinediones and thiazolidinediones: Pyridinyloxyphenyl and pyridinyloxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.... Agent: Merck And Co., Inc

20090069386 - Liquid composition, process for producing the liquid composition,and ectoparasite controlling agent for use in mammals and avians: A liquid composition comprising (a) 21 to 70 parts by weight of a solvent having no nitrogen atom and having a carbonyl or sulfonyl group in the molecule, (b) 30 to 78.9 parts by weight of at least one component selected from the group consisting of a non-cyclic alcohol, an... Agent: Kenyon & Kenyon LLP

20090069387 - Animal parasite-control method using insect growth regulators: Methods and formulations for treating animal ectoparasites, effective against parasites such as fleas and ticks are provided. The methods comprise topically co-administering a non-mobile insect growth regulator, a mobile insect growth regulator, and an adulticide to the animal. Parasiticidal formulations for treating animal ectoparasites are also provided, which can be... Agent: Stroock & Stroock & Lavan LLP

20090069388 - Deuterium-enriched sorafenib: The present application describes deuterium-enriched sorafenib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069389 - Novel controlled release-niacin formulation: The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and maintains its release pattern without fluctuation for a desired time period, unlike a commercial formulation. In particular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of... Agent: Casimir Jones, S.c.

20090069390 - Deuterium-enriched rufinamide: The present application describes deuterium-enriched rufinamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069391 - Benzothiophene hydroxamic acid derivatives: The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells,... Agent: Merck And Co., Inc

20090069394 - Cancer treatment with epothilones: The present invention relates to an in vivo regimen for the treatment of a proliferative disease, including non small cell lung carcinoma, where an epothilone, including epothiline B, is administered in a loading dose followed by at least one maintenance doses.... Agent: Novartis Corporate Intellectual Property

20090069392 - Composition that prevents damage to trees by harmful insects and a prevention method thereof: The present invention relates to a composition comprising a neonicotinoid-based compound having a high degree of insecticidal activity, a surfactant, and an organic solvent, which is capable of demonstrating stable effects and in which the types and amounts of surfactant and organic solvent are adjusted so as to prevent chemical... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090069393 - Parenteral formulation for epothilone analogs: A process for formulating certain epothilone analogs for parenteral administration is disclosed wherein the analog is dissolved in a mixture of at least 50% by volume tertiary-butanol in water, the mixture is lyophilized, the resulting lyophilized product is packaged in one vial with a sufficient amount of solvent comprising anhydrous... Agent: Louis J. Wille Bristol-myers Squibb Company

20090069395 - Deuterium-enriched famotidine: The present application describes deuterium-enriched famotidine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069396 - Polyene oxazoles and processes for their preparation: This invention relates to novel biologically active polyene oxazoles, their pharmaceutically acceptable salts and derivatives, and to methods of obtaining them. One method for obtaining the compounds is by cultivation of Streptomyces sparsogenes NRRL 2940 or a mutant or variant thereof.... Agent: Merchant & Gould PC

20090069397 - Deuterium-enriched olmesartan: The present application describes deuterium-enriched olmesartan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069398 - Pyrazolyl carboxamides: e

20090069399 - Deuterium-enriched frovatriptan: The present application describes deuterium-enriched frovatriptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069400 - Indole sulfonamide modulators of progesterone receptors: Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.... Agent: Eli Lilly & Company

20090069401 - Marine actinomycete taxon for drug and fermentation product discovery: The invention is the discovery of an actinomycete genus, given the name Salinospora gen. nov., that displays an obligate requirement of seawater (Na+) for growth and unique 16S rRNA signature nucleotides. The invention is also the use of the genus for the production and discovery of active biomolecules such as... Agent: Dla Piper LLP (us)

20090069402 - Deuterium-enriched atrasentan: The present application describes deuterium-enriched atrasentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069403 - Composition and method for reducing allergen: This invention relates to an allergen-reducing composition comprising a hydroxyproline derivative, a polymer thereof, or a salt of such a derivative or polymer, which is capable of reducing the allergenicity of mites, pollens, or other allergens and is capable of imparting functions of reducing allergenicity to fibers or textiles such... Agent: Fitzpatrick Cella Harper & Scinto

20090069404 - Deuterium-enriched vernakalant: The present application describes deuterium-enriched vemakalant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069406 - Analogs of tetramic acid: Tetramic acid analogues of Formula I and Formula II have antibacterial activity, primarily against gram-positive bacteria, and are iron chelators.... Agent: Howard Eisenberg, Esq.

20090069405 - Treatment of cns and pain disorders: A method of treating a patient suffering from a condition or disorder selected from chronic pain, neuropathic pain, fibromyalgia, migraine, bipolar disorder and depression comprises the administration of a pharmacologically effective amount of 3-(phenylmethylamino-methylene)pyrrolidine-2,4-dione (I) or a pharmaceutically acceptable salt or prodrug or solvate thereof. Also disclosed is the use... Agent: Dickstein Shapiro LLP

20090069407 - Compounds, compositions and methods for repelling blood-feeding arthropods and deterring their landing and feeding: This invention relates to compositions of one or more compounds that incorporate one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties, or one or more allyl sulfide, allyl disulfide or allyl polysulfide moieties and one or more hydroxyl groups, used in effective amount in formulations, including emulsions, to... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20090069408 - Tricyclic compounds useful in treating iron disorders: wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the... Agent: SeedIPLaw Group PLLC

20090069410 - Deuterium-enriched paclitaxel: The present application describes deuterium-enriched paclitaxel, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069409 - Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions: The invention relates to pharmaceutical compositions comprising anhydrous(2R,3S)4-acetoxy-2-a-benzoyloxy-5β-20-epoxy-1,7-β-10-β-tri-hydroxy-9-oxo-tax-11-en-13α-il 3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate (I)(docetaxel) and 4-acetoxy-2-α-benzoyloxy-5-β-20-epoxy-1,7β-10-β-tri-hydroxy-9-oxo-tax-11-en-13α-il (2R, 3S)3-benzoylamino-2-hydroxy-3-phenylpropionate (II) (paclitaxel), methods for treating neoplastic tumors using anhydrous docetaxel and paclitaxel, and a process for the preparation of the anhydrous docetaxel and paclitaxel.... Agent: Birch Stewart Kolasch & Birch

20090069411 - Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids: The present invention relates to novel formulations of taxoids for oral administration. More particularly, the present invention discloses and claims self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090069413 - Deuterium-enriched olopatadine: The present application describes deuterium-enriched olopatadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069412 - Deuterium-enriched sugammadex: The present application describes deuterium-enriched sugammadex, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069415 - Deuterium-enriched nebivolol: The present application describes deuterium-enriched nebivolol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069414 - Epicatechin and vasodilation: This invention relates to compositions comprising epicatechin and method of use of such compositions for inducing vasodilation of blood vessels in humans and veterinary animals.... Agent: Nada Jain, P.C.

20090069416 - Cosmetic composition for skin and wrinkle improver: i

20090069417 - Carotenoid oxidation products as chemopreventive and chemotherapeutic agents: The present invention relates to a method for the chemoprevention and treatment of cancer, by administering a pharmaceutical composition comprising a carotenoid derivative, such as a derivative of lycopene, a- and b-carotene, phytoene, phytofluene, lutein, zeaxanthin, α- and β-cryptoxanthin, canthaxanthin, astaxanthin, or other carotenoid. The carotenoid derivative is a carotenoid... Agent: Nixon & Vanderhye, PC

20090069418 - Compositions and methods for the treatment of disorders associated with aberrant vasodilation: Methods and compositions for the treatment of conditions associated with improper vasodilation are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090069419 - Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use: Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090069420 - Small molecule inhibitors of stat3 with anti-tumor activity: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090069421 - Crystal polymorph of hydroxynorephedrin derivative hydrochloride: The present invention provides a novel crystal polymorph of ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride which can be determined by characteristic diffraction peaks of the powder X-ray diffraction or the like, and obtained from ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method.... Agent: Sughrue Mion, PLLC

20090069422 - Composition and method for increasing the anabolic state of muscle cells: A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle... Agent: Torys LLP

20090069423 - Compounds, compositions and methods for producing antioxidants from carnitine: Carnitines are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to produce longer chain fatty acid esters of carnitines such as polyunsaturated fatty acid esters including eicosapentaenoyl-L-carnitine and/or docosahexaenyl-L-carnitine in germinating plant seeds. The resulting products from the plant seeds are... Agent: Lesavich High-tech Law Group, P.C.

20090069424 - Tgf-alpha expression inhibitors: An inhibitor against TGF-α expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant... Agent: Greenblum & Bernstein, P.L.C

20090069425 - Active composition for treatment or prevention of problems related to a disturbance of the biological clock: A composition contains polyunsaturated fatty acids and flavonoids as active substances. A method treats disorders caused by disturbance of a biological clock in humans and animals and includes administering a therapeutically effective amount of the composition to a human or animal. A method regulates the biological clock in a mammal... Agent: Ip Group Of Dla Piper US LLP

20090069426 - Methods for reducing the amount of a proinflammatory substance in animal tissue or body fluid: A method for reducing the amount of a proinflammatory substance present at an elevated level in animal tissue or body fluid by orally administering to the animal a proinflammatory substance reducing amount of a composition comprising at least one omega-3 fatty acid. The method is useful for reducing inflammation caused... Agent: Colgate-palmolive Company

20090069427 - Alpha-2-delta ligands for non-restorative sleep: The use of an alpha-2-delta ligand or a pharmaceutically acceptable salt thereof for the treatment of non-restorative sleep is disclosed.... Agent: Pfizer Inc Steve T. Zelson

20090069428 - Catalytic antioxidants and methods of use: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substrates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with... Agent: Darby & Darby P.C.

20090069429 - Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance: This invention relates to a composition comprising Alpha-ketoglutarate (AKG) for modulating muscle performance in a mammal including a human being. Also contemplated is a method for modulating muscle performance in a vertebrate, including mammal and bird, and the manufacture of a composition for the prevention, alleviation or treatment of muscle... Agent: Morrison & Foerster LLP

20090069430 - Dibenzene derivatives as calcium channel blockers: i

20090069431 - Deuterium-enriched milnacipran: The present application describes deuterium-enriched milnacipran, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069432 - Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed... Agent: Jones Day

20090069433 - Nasal rinse additive: A nasal rinse additive composition includes oleoresin capsicum containing capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homodihydrocapsaicin, and homocapsaicin as active ingredients. The nasal rinse additive composition can further include vegetable glycerin, purified water, spearmint oil, lemongrass oil, sea salt, and/or ascorbic acid. The composition can be used to relieve and/or prevent pain, dryness,... Agent: Amin Hallihan, LLC

20090069434 - Cystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it: n

20090069435 - Bridged polycyclic compound based compositions for topical applications for pets: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090069436 - Antimicrobial skin composition comprising a biguanide or a quaternium compound: An antimicrobial skin treatment composition comprises 0.001-5% w/w of a biguanide compound and/or 0.001-5% w/w of a quaternary ammonium compound. The composition may be a skin rub, in which case it may additionally comprise at least one alcohol, at least one lipogel and at least one oil. Alternatively the composition... Agent: Connolly Bove Lodge & Hutz LLP

20090069437 - Compositions for oral transmucosal delivery of metformin: The invention relates to oral transmucosal pharmaceutical compositions comprising metformin or a pharmaceutically acceptable salt thereof, methods of using the compositions to treat various conditions, including diabetes, methods of preparing the compositions, and preparations for use in making the compositions.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090069438 - Poly-halogenated triazapentadiene compositions: A new class of fluorinated or polyhalogenated triazapentadienes are disclosed. The synthesized triazapentadienes are thermally stable, soluble in typical solvents and have several metal binding sites for complexation with metal ions. The compounds are prepared as colorless crystalline solids. Synthesis takes advantage of a reaction with triethylamine. Synthesized triazapentadienes (with... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20090069439 - Use of pargyline for the treatment of hair folliclies: Use of Pargyline for the production of a medicament for influencing the metabolism of hair follicles and the modulation of their vital cycle.... Agent: Dilworth & Barrese, LLP

20090069440 - Deuterium-enriched atomoxetine: The present application describes deuterium-enriched atomoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090069441 - Motuporamine mimic agents: Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.... Agent: Beusse Wolter Sanks Mora & Maire

20090069442 - Therapeutic agent for sensory abnormality: The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090069443 - Sedative effect-imparting agent and sedative perfume composition containing the same: e

20090069444 - Method to ameliorate oxidative stress and improve working memory via pterostilbene administration: Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20090069445 - Propofol-containing fat emulsions: This invention provides a propofol-containing fat emulsion preparation including: 0.1 to 2 w/v % of propofol, 10 to 20 w/v % of an oily component, and 2 to 5 w/v % of an emulsifier, the weight of the oily component being in the range of about 5 to about 200... Agent: Sughrue Mion, PLLC

20090069446 - Dendritic salt therapeutic agent delivery system: A therapeutic agent delivery system includes a therapeutic agent, a dendritic salt used as a carrier to effectively deliver the therapeutic agent, and a salt base. The system can include the dendritic salt and the salt base in a ratio of about 1 part dendritic salt to about 8 parts... Agent: Amin Hallihan, LLC

20090069447 - Bright pigment with gold tone, and cosmetic, paint, ink or resin composition containing the same: A bright pigment with a gold tone of the present invention includes a scaly glass substrate 10, a base coating 20 containing at least one metallic material selected from the group consisting of silver, nickel and a nickel-based alloy, a gold coating 30 containing gold and a yellow coating 40... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090069448 - Degradable polymer and process for production thereof: In one embodiment of the present invention, a degradable polymer having a peroxide bond therein is disclosed. The degradable polymer can be utilized in the fields of medicals or medical materials, can be applied to a DDS or gene delivery system, and can be used as a novel polymeric material... Agent: Harness, Dickey & Pierce, P.L.C

20090069449 - Ethambutol based nitric oxide donors: The present invention relates generally to nitric oxide releasing pharmaceutical compounds. More particularly, the present invention relates to pharmaceutical compositions that release nitric oxide under physiological conditions. In one embodiment, the present invention relates to new chemical compounds—diazeniumdiolates nitric oxide donors—that are based on ethambutol possessing physiological and biomedical activity.... Agent: Roetzel And Andress

  
03/05/2009 > patent applications in patent subcategories. listing by industry category

20090062179 - Diagnosing and treating hormone resistant cancers: Provided herein are methods and compositions related to diagnosing and treating hormone resistant cancers.... Agent: Fish & Richardson P.C.

20090062178 - Methods of use of gamma inhibitor compounds for the attenuation of pain: The disclosure herein relates to modified γPKC inhibitory peptides, methods of generating such peptides, and method for using γPKC inhibitory peptides for the treatment of pain.... Agent: Morrison & Foerster LLP

20090062180 - Glycogen synthase kinase-3 inhibitors: Novel conjugates that are capable of inhibiting GSK-3 activity, a process of producing same, pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions are disclosed. Methods of treating affective disorders using GSK-3 inhibitors are further disclosed.... Agent: Martin D. Moynihan Prtsi, Inc.

20090062181 - Mineral collagen chelates and methods of making and using same: Collagen peptide chelated mineral products, pharmaceutical formulations thereof and methods for preparing same are provided. Also provided is a method for generating the optimal size of collagen peptide for optimum mineral chelation as well as optimum biological function for supporting bone health and joint health. Also disclosed are methods of... Agent: Gibson & Dernier L.L.P.

20090062182 - Deuterium-enriched dalbavancin: The present application describes deuterium-enriched dalbavancin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062183 - Modulation of synaptogenesis: Soluble proteins, e.g. thrombospondins, can trigger synapse formation. Such proteins are synthesized in vitro and in vivo by astrocytes, which therefore have a role in synaptogenesis. These thrombospondins are only expressed in the normal brain exactly during the period of developmental synaptogenesis, being off in embryonic brain and adult brain... Agent: Morrison & Foerster LLP

20090062185 - Deuterium-enriched anidulafungin: The present application describes deuterium-enriched anidulafungin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062184 - Fine particulate preparation comprising complex of nucleic acid molecule and collagen: The present invention relates an additive comprising at least one substance selected from arginine, trometamol, meglumine, lysine, histidine, monoethanolamine, diethanolamine, triethanolamine, succinic acid, citric acid, tartaric acid, lactic acid, and salts thereof, which is useful in the prevention of aggregation of fine particulate complexes of a nucleic acid and collagen,... Agent: Birch Stewart Kolasch & Birch

20090062186 - Compounds binding to p-selectin: The present invention relates to derivatives of compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such derivatives which comprise a peptide moiety or a functional equivalent of said peptide moiety and are represented by X(Ax)mA3A1A2A1Y. In addition, the invention relates to methods for preparing such... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090062191 - Composition for maintaining gastrointestinal homeostasis: The invention relates to a suspension of albumin and tannic acid for maintaining gastrointestinal homeostasis.... Agent: Marla J. Church, Esq. Kiel Laboratories, Inc.

20090062193 - Compositions and methods for the control, prevention and treatment of obesity and eating disorders: Compositions and methods for preventing, treating or controlling conditions or disorders associated with obesity, diet, and nutrition are provided. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to prevent, treat or controlling conditions or disorders associated with obesity, diet,... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090062194 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20090062204 - Compositions and methods for treating and preventing gastroenteric diseases: A model system to study extracellular enteric bacterial pathogen (e.g., Y. enterocolitica) infection of murine neonates through the natural orogastric (o.g.) route of transmission has been developed. The experiments described herein led to the discoveries that 1) murine neonates are resistant to intestinal Yersinia enterolcolitica infection, 2) neonatal mice mount... Agent: Akerman Senterfitt

20090062196 - Compositions and methods of treating cancer: This present invention compositions and methods of treating cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090062192 - Dimeric peptide agonists of the glp-1 receptor: Dimerization of GLP-1 agonists and therapeutic uses thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090062203 - Dipeptidyl peptidase iv inhibitors for the treatment of schizophrenia and depression: A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or... Agent: Sonnenschein Nath & Rosenthal LLP

20090062188 - Disease-associated protein: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090062201 - Integrin binding motif containing peptides and methods of treating skeletal diseases: Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in... Agent: Bozicevic, Field & Francis LLP

20090062195 - Kallikrein-inhibitor therapies: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.... Agent: Lowrie, Lando & Anastasi, LLP

20090062198 - Maurotoxin, pi1 and hstx1 derivatives: Derivatives of Maurotoxin (MTX) in which the native disulfide bridge pattern (Cys3-Cys24, Cys9-Cys29, Cys19, Cys31-Cys34) has been disrupted are useful for the treatment of pathologies associated with dysfunctioning and/or activation of Ca2+-activated and/or voltage-gated K+ channel subtypes, such as IKCa1 or Kv1.2. One preferred group of derivatives is that in... Agent: Clark & Elbing LLP

20090062202 - Methods of treating and preventing pressure ulcers with intradermal and transdermal delivery of calcitonin gene-related peptide (cgrp): A method of treating ischemic skin pressure ulcers and helping such ulcers heal has the steps of a. debriding the ulcer as necessary to produce a clean, largely uncontaminated surface; and b. applying calcitonin gene-related peptide (CGRP) intradermally or transdermally to the periphery of the ulcer, the CGRP being administered... Agent: The Luther Law Firm, PLC

20090062199 - Nogo receptor polypeptides and polypeptide fragments and uses thereof: Nogo receptor 1 (NgR1) is a leucine rich repeat protein that forms part of a signaling complex that modulates axon regeneration. Previous studies have shown that the entire LRR region of Nogo receptor-1, including the C-terminal cap of LRR, LRRCT, is needed for ligand binding, and that the adjacent CT... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090062205 - Reconstitution medium for protein and peptide formulations: Compositions useful for reconstitution of concentrated formulations containing protein/peptide pharmaceuticals are provided. The composition generally includes one or more lipids, as well as one or more alcohols that promote and stabilize the formation of (a) lipid molecular assemblies with greater protein encapsulation; (b) protein-lipid complexes and (c) protein and lipid... Agent: Hodgson Russ LLP The Guaranty Building

20090062197 - Sp1 polypeptides, modified sp1 polypeptides and uses thereof: SP1 and modified SP1 variant polypeptides capable of forming reversible molecular associations with substances, compositions-of-matter comprising same, and uses thereof are provided.... Agent: Martin D. Moynihan Prtsi, Inc

20090062190 - Transcriptional regulation of cytokines by litaf and stat (6)(b): The present invention relates to novel proteins (LITAF and STAT6(B)) and the nucleotide sequences encoding the same. The present invention also relates to the use of the novel peptides and nucleotide sequences of the present invention, or functional fragments thereof, for the regulation of cytokine expression. The present invention also... Agent: Kevin M. Farrell Pierce Atwood

20090062189 - Tumor suppressor protein and nucleotide encoding same: e

20090062206 - Urodilatin cancer treatment: Urodilatin, a peptide formed in the kidney, has significant anticancer effects eliminating two-thirds of cancer cells within 24 hours.... Agent: Smith Hopen, Pa

20090062187 - Use of hmgb1 for wound healing: The present invention describes the role of HMGB1 in improving wound healing, in particular in a model of diabetes. Other evidences based on the effect of glycyrrhizin, the underexpression of HMGB1 in the skin and fibroblast of diabetic subjects, the accumulation of RAGE in the skin of diabetic mice and... Agent: Juneau Partners

20090062200 - Vegf-binding fusion proteins and therapeutic uses thereof: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.... Agent: Regeneron Pharmaceuticals, Inc

20090062207 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction... Agent: Fish & Richardson PC

20090062208 - Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-pkc inhibitor: Methods for maintaining the integrity of the blood-brain barrier are described. Compounds that act to inhibit the action of the delta isozyme of protein kinase C (PKC) to prevent disruption of the blood-brain barrier in hypertensive subjects are described, to, in one embodiment, decrease the likelihood of hypertension-induced stroke or... Agent: Perkins Coie LLP

20090062209 - Methods of use of epsilon inhibitor compounds for the attenuation of pain: The disclosure herein relates to modified εPKC inhibitory peptides, methods of generating such peptides, and method for using εPKC inhibitory peptides for the treatment of pain.... Agent: Morrison & Foerster LLP

20090062211 - Conopeptides and methods of use: Isolation, synthesis and therapeutic use of conotoxin and conophan compounds and related compositions including a new class of conopeptides including the modified amino acid D-γ-hydro-oxyvalinie (D-Hyv=V*) are described herein. These isolated peptides are the first known example of a naturally occurring polypeptide chain containing D-Hyv. The active peptides, termed γ-Hydroxyconophans... Agent: Akerman Senterfitt

20090062210 - Methods for promoting erythropoiesis: The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090062212 - Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2: Neurotensin analogs selective for neurotensin receptor subtype 2 are described. These include hexapeptides (NT(8-13)) and pentapeptides (NT(9-13)) having a D-3,1-naphthyl-alanine, D-3,2-naphthyl-alanine, an alanine derivative such as cyclohexylalanine, or 1,2,3,4-tetrahydroisoquinoline at position 11. Methods of treating pain by administering these neurotensin analogs are also described.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20090062213 - Small molecule inhibitors of pdz interactions: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.... Agent: Townsend And Townsend And Crew, LLP

20090062215 - Application of d-psicose to suppression of abnormal circadian increase in blood glucose level: A novel use of D-psicose (for suppressing the abnormal intra-day increase of blood glucose level) is provided. A composition containing D-psicose as the active component and for use in suppressing the abnormal intra-day increase of plasma glucose concentration. The composition is a composition in blend with D-psicose and/or a derivative... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090062216 - Butanol extract of bidens pilosa: wherein R1 is H, alkyl, aryl, or cyclyl; R2 is pyranose; R3 is H or alkyl; m is 2, 3, 4, 5, or 6; n is 0, 1, 2, or 3; o is 0, 1, 2, 3, 4; p is 1, 2, 3, or 4; and the Th1-mediated disorder is... Agent: Occhiuti Rohlicek & Tsao, LLP

20090062214 - Left-side glucose lipid a analogue: e

20090062217 - Promoter for the production of hyaluronic acid containing ginsenoside compound k: There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng saponin, to increase the expression of hyaluronic acid synthase gene in human cell and thereby to promote the production of... Agent: Sughrue Mion, PLLC

20090062221 - Azithromycin for treatment of skin disorders: Azithromycin has increased efficacy in treating acne and other skin conditions when administered systemically at low doses, below those previously known to produce a clinical antibiotic effect.... Agent: Howard Eisenberg, Esq.

20090062220 - Deuterium-enriched azithromycin: The present application describes deuterium-enriched azithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062219 - Drugs for the treatment and/or prophylaxis of gastroparesis symptom: (wherein R1 represents a C1-C6 alkyl group and R2 represents a C1-C6 alkyl group) or a pharmaceutically acceptable salt thereof as an active ingredient. The erythromycin derivative of the formula (1) has an efficacy of improving gastroparesis and this action of the derivative in improving gastroparesis symptom is not found... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090062218 - Macrolone compounds: h

20090062222 - Methods for sensitizing cancer cells to inhibitors: The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies.... Agent: Ronald I. Eisenstein

20090062223 - Amino tricyclic-nucleoside compounds, compositions, and methods of use: Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds and compositions are useful for treating viral infections caused by the Flaviviridae family of viruses.... Agent: Genelabs Technologies, Inc. C/o Foley & Lardner LLP

20090062225 - Compositions and methods for inhibiting expression of a gene from the jc virus: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to... Agent: Alnylam/fenwick

20090062229 - Method and composition for reducing the expression of rock-ii: Methods and compositions for reducing the expression of Rho-associated, coiled-coil containing protein kinase 2 (ROCK-II) are provided.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20090062226 - Method and compositions for inhibiting mage protein interaction with kap-1: Method for inhibiting tumor cell formation or tumor cell growth, and method for inducing apoptosis in sperms, the method comprising administering to a patient in need thereof an antagonist that inhibits the binding of MAGE protein to KAP-1, thereby inhibiting MAGE gene function. Also disclosed are pharmaceutical compositions comprising the... Agent: Kening Li Pinsent Masons

20090062227 - Methods and compositions for inducing apoptosis by stimulating er stress: The present invention provides a method for inducing apoptosis in selected cells by aggravating ER-stress. The aggravation of ER-stress is achieved in a specific manner by inhibiting SERCA (sarcoplasmic/endoplasmic reticulum calcium ATPase), leading to elevated level of cytoplasmic calcium concentration, yet without inhibiting the activity of COX-2 (cyclooxygenase-2) or triggering... Agent: Hogan & Hartson L.L.P.

20090062230 - Novel cationic 17 alpha-substituted-estradiol derivatives useful as anti-cancer agent: The present invention provides a novel series of cationic, lipid-based, 17α-substituted-estradiol derivatives. The present invention further provides a process for the preparation of a novel series of 17α-substituted-estradiol derivatives. The invention also provides information about highly selective anticancer activities of these molecules in estrogen responsive cell lines. The compound elicits... Agent: Dla Piper LLP (us)

20090062228 - Pirna and uses related thereto: The invention relates to small single stranded RNAs and analogs thereof (collectively “piRNA” herein), compositions comprising such piRNAs, and their uses in regulating target gene expression or as markers for certain disease states.... Agent: Ropes & Gray LLP

20090062224 - Therapeutic use of cpg oligodeoxynucleotide for skin disease: Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.... Agent: Casimir Jones, S.c.

20090062231 - Appetite suppressant composition and method of appetite suppression: The present invention provides an appetite suppressant composition including alginate, hydroxycitric acid, and piperine. The present invention also provides an appetite suppressant composition including alginate, hydroxycitric acid, and garcinol. The present invention further provides a method of suppressing appetite utilizing an appetite suppressant composition for creating an immediate and sustained... Agent: Amin Hallihan, LLC

20090062232 - High-purity xylooligosaccharide compositions: A high-pure xylooligosaccharide composition containing reduced UV-absorbing substances and reduced coloring matters and a method of producing the same which comprises alkali-treating or pressure- and heat-treating a plant material such as wood, corn cob, cotton seed hull, bagasse or rice straw, further enzymatically treating the same, and purifying the crude... Agent: Drinker Biddle & Reath (dc)

20090062233 - Modified starch material of biocompatible hemostasis: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves... Agent: David And Raymond Patent Firm

20090062234 - Substituted organopolysiloxanes and use thereof: The invention relates to new compounds of Formula (1): wherein Q is selected from CXYR′ and RC(Z) wherein Z is selected from oxygen, hydrogen, OH, NR2 and NNR2R3, and wherein X and Y are each selected from hydrogen, RC(Z), CN or C(O)W and W is selected from OH, OR6, O(M+″)1/″... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090062235 - Inhibitors of dipeptidylpeptidase iv: The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090062236 - Programmable genotoxic agents and uses therefor: The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as... Agent: Wolf Greenfield & Sacks, P.C.

20090062237 - Evaluating immune competence: This document relates to methods and materials involved in evaluating immune competence in a subject. For example, methods and materials for evaluating immune competence in a subject to BK virus (BKV) are provided. Also provided are isolated peptides, compositions, and methods useful for evaluating whether or not a subject is... Agent: Fish & Richardson P.C.

20090062238 - Method for treatment of neuropathic pain: Compounds and methods useful for preventing and treating pain, e.g., neuropathic pain, in a subject in need thereof are provided. The compounds can be “S1P modulating” agents that are capable of inducing a detectable change in S1P receptor activity.... Agent: Iplm Group, P.A.

20090062239 - Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery: Disclosed herein are methods of preventing, inhibiting, or ameliorating complications associated with cardiopulmonary bypass surgery by the use of a thrombin receptor antagonist compound. Among the thrombin receptor antagonist compounds useful in these methods are those of Formulas I and II, described herein. Examples of such thrombin receptor antagonists include:... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090062240 - Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate: The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the... Agent: Crowell & Moring LLP Intellectual Property Group

20090062241 - Highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090062242 - Methods and compositions for treating gastrointestinal conditions: Methods and compositions for treating a condition involving gastrointestinal symptoms comprising administering to a patient in need of such treatment an effective amount of a P-glycoprotein substrate, wherein the P-glycoprotein substrate is a compound exhibiting an efflux inhibition ratio (EIR) of greater than or equal to 0.4, wherein the P-glycoprotein... Agent: Greenblum & Bernstein, P.L.C

20090062243 - Lupane-type triterpenoids modified at 30-position and analogues thereof: The present invention comprises lupine-type triterpenoids that inhibit cell proliferations, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090062245 - Modulation of neurodegenerative diseases through the progesterone receptor: Methods for modulating hormonal pathways involving the progesterone receptor in a subject with a neurodegenerative disorder, are provided. Progesterone receptor activity is modulated by administering an effective amount of an progesterone receptor modulating pharmacological agent to a subject such that the progesterone receptor modulating pharmacological agent interacts with the progesterone... Agent: Nutter Mcclennen & Fish LLP

20090062244 - Pharmaceutical composition: Topical composition for enhanced local and systemic delivery of poorly soluble biologically active compounds, comprises of non-volatile solvent or mixture of solvents to dissolve active component, and moisture absorbent or mixture of sorbents to prevent precipitation or crystallization of insoluble material after application... Agent: Alpharx Inc.

20090062247 - Methods for inhibiting tgf-beta: The present invention provides methods for inhibiting or blocking TGF-β activity in cells and/or tissues expressing TGF-β comprising, contacting cells and/or tissues expressing TGF-β with an amount of cholesterol or cholesterol derivative effective to inhibit the activity of TGF-β. The present invention further provides a method for treating a condition... Agent: Elmore Patent Law Group, P.C.

20090062246 - Therapeutic treatment-014: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an aromatase inhibitor or an estrogen receptor down-regulator is described. The combination is expected to be useful in the treatment of cancer.... Agent: Astrazeneca R&d Boston

20090062248 - Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing... Agent: Townsend And Townsend And Crew, LLP

20090062249 - Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Allergan, Inc.

20090062250 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Foley Hoag, LLP (w/ipx)

20090062251 - Novel compounds 002: e

20090062252 - Therapeutic isoxazole compounds: wherein A1, A2, A3, R1, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are... Agent: Knobbe Martens Olson & Bear LLP

20090062253 - Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090062254 - Acute treatment of headache with phenothiazine antipsychotics: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.... Agent: Swanson & Bratschun, L.l.c

20090062255 - Tumor-targeting evaluation methodology and compounds related thereto: The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said... Agent: Merchant & Gould PC

20090062256 - Lactams substituted by cyclic succinates as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20090062257 - Deuterium-enriched varenicline: The present application describes deuterium-enriched varenicline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062258 - Fused pyrimidine derivative and use thereof: wherein: ring A is a 5-membered aromatic heterocycle optionally having substituent(s); R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); W is an oxygen atom or a sulfur atom; X1 and X2 may be the same or different and each is a hydrogen atom, a hydrocarbon group... Agent: Edwards Angell Palmer & Dodge LLP

20090062260 - Compounds and compositions as lxr modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).... Agent: Genomics Institute Of The Novartis Research Foundation

20090062259 - Bezothiazol derivatives as beta2 adrenoreceptor agonists: The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The... Agent: Fish & Richardson P.C.

20090062261 - Nitrogen-containing heterocycle derivatives substituted with cyclic group: e

20090062262 - Non steroidal glucocorticoid receptor modulators: The present invention relates to compounds having general Formula (I) or a pharmaceutically acceptable salt thereof. In this formula R1 is H or (1-4C)alkyl; R2 is —C(O)R15 or —S(O)2R15; R3 is H, (1-4C)alkyl or —OR16; R4 is H, (1-4C)alkyl or —OR16; R6 is H or —C(H)NOR16; R7 is H or... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090062263 - 4-hydroxy-5,6-dihydro-1h-pyridin-2-one compounds: The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20090062264 - Salts of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing... Agent: Foley & Lardner LLP

20090062265 - Pyrrolo-quinoxalinone derivatives as antibacterials: Tricyclic nitrogen containing compounds and their use as antibacterials.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090062266 - Oxazolidinone compounds, and compositions and methods related thereto: The invention provides new oxazolidinone compounds of formula (I) wherein A is certain heterocycles optionally substituted; R1, R2, R3 and R4 are independently selected from —H and halogen; X is selected from O, S, NR9 and CR9R10; R9 and R10 having different meanings; Y is selected from O, S, SO,... Agent: Birch Stewart Kolasch & Birch

20090062267 - L-alanine derivatives as a5beta1 antagonists: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that... Agent: Astrazeneca R&d Boston

20090062269 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090062268 - Novel inhibitors of poly(adp-ribose)polymerase (parp): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and... Agent: Wilson Sonsini Goodrich & Rosati

20090062270 - Spiro 2,4 pyrimidinediamine compounds and their uses: The present invention provides methods of treating or preventing autoimmune diseases with spiro 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms,... Agent: Rigel Pharmaceuticals Inc.

20090062271 - Antithrombotic diamides: This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.... Agent: Eli Lilly & Company

20090062272 - Imidazoquinolinyl sulfonamides: Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamide compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090062273 - 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same.: in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts, N-oxides, solvates and prodrugs thereof, to pharmaceutical compositions comprising said 3-H-pyrazolopyridine compounds, to methods of preparing said 3-H-pyrazolopyridines, to intermediate compounds useful in said methods, to uses of... Agent: Millen, White, Zelano & Branigan, P.C.

20090062275 - N-substituted imidazopyridine c-kit inhibitors:

20090062276 - Pyridopyrimidine protein tyrosine phosphatase inhibitors:

20090062274 - Pyridopyrimidinone inhibitors of pi3kalpha: The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.... Agent: Patent Dept Exelixis, Inc.

20090062278 - 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication: e

20090062277 - Phosphodiesterase 10 inhibitors: where R1, R2, R3, R4, X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the... Agent: Jones Day

20090062281 - 3-quinolinecarbonitrile protein kinase inhibitors: where Ar, X, R1, R2, R3, and R4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps,... Agent: Wyeth Patent Law Group

20090062279 - Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents: The invention is related to compound which comprises at least one radical C═Y, Y being O or S, and an oxidable and non protonable nitrogen atom N wherein the distance (d) between the at least one carbon atom of the radical group C═Y and the nitrogen atom, when oxidized, is... Agent: Marsh, Fischmann & Breyfogle LLP

20090062280 - Ophthalmic compositions for treating ocular hypertension: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect... Agent: Merck And Co., Inc

20090062282 - Substituted amino-pyrimidones and uses thereof: This invention relates to novel compounds having the structural formula Ia or formula Ib below: (Ia, Ib), and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Aβ related pathologies such as cognitive impairment,... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090062283 - Deuterium-enriched linezolid: The present application describes deuterium-enriched linezolid, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062284 - Thio-substituted biarylmethanesulfinyl derivatives: wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue... Agent: Cephalon, Inc.

20090062285 - Sulfur-containing compound, method of preparation and pharmaceutical uses thereof: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of... Agent: Husch Blackwell Sanders LLP

20090062286 - Crystal structure of smyd3 protein: The invention relates to SMYD3 methyltransferase (SMYD3), SMYD3 binding pockets or SMYD3-like binding pockets. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090062287 - Substituted biaryl compounds as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, and ring B are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin,... Agent: Louis J. Wille Bristol-myers Squibb Company

20090062288 - Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.... Agent: Jones Day

20090062290 - Heterocycles as potassium channel modulators: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia,... Agent: Townsend And Townsend And Crew, LLP

20090062289 - Immunomodulating oxopyrrazolocinnolines as cd 80 inhibitors: N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide is a CD80 antagonist, useful in the treatment of dieases which benefit from immuno-inhibition.... Agent: Banner & Witcoff, Ltd.

20090062291 - Phosphodiesterase 10 inhibitors: where R1, R2, R3, R4, X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the... Agent: Jones Day

20090062292 - Tetrahydropteridines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Miller Canfield Paddock And Stone PLC

20090062293 - 1,4-substituted piperazine derivatives: This compound has a metabotropic glutamate receptor 1 inhibitory effect, and therefore is useful for the treatment of a brain disorder such as convulsion, acute pain, inflammatory pain, chronic pain, cerebral infraction or transient cerebral ischemic attack, a mental dysfunction such as schizophrenia, and a disease such as anxiety and... Agent: Merck And Co., Inc

20090062294 - Heteroaryl-substituted urea modulators of fatty acid amide hydrolase: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating... Agent: Philip S. Johnson Johnson & Johnson

20090062295 - Pharmaceutical products: Pharmaceutical products comprising 6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone or a salt thereof, or a hydrate thereof or a solvate thereof as an active ingredient, wherein production of hydrazine is substantially suppressed is provided.... Agent: Greenblum & Bernstein, P.L.C

20090062296 - Prostaglandin derivatives: Nitroderivatives of prostaglandin amides having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Pfizer Inc

20090062297 - Hydroxyalkylarylamide derivatives: The present invention relates to a novel class of hydroxyalkylarylamide derivatives. The instant compounds can be used to treat cancer. The fluorinated arylamide derivatives can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting... Agent: Merck And Co., Inc

20090062298 - Deuterium-enriched sildenafil: The present application describes deuterium-enriched sildenafil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062299 - Deuterium-enriched doxazosin: The present application describes deuterium-enriched doxazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062300 - Deuterium-enriched prazosin: The present application describes deuterium-enriched prazosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062301 - Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one ja k3 kinase inhibitor for treating autoimmune disorders: The present invention relates to a pharmaceutical combination comprising at least one PKC inhibitor, in particular indolylmaleimide derivatives, and at least one JAK3 kinase inhibitor and the uses of such a combination e.g. in autoimmune diseases, e.g. in preventing or treating type I diabetes mellitus and disorders associated therewith, or... Agent: Novartis Corporate Intellectual Property

20090062302 - Jak2 tyrosine kinase inhibition: The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.... Agent: Merck And Co., Inc

20090062303 - Deuterium-enriched ziprasidone: The present application describes deuterium-enriched ziprasidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062304 - Benzimidazole derivatives and their use for modulating the gaba-alpha receptor complex: e

20090062305 - Deuterium-enriched cetirizine: The present application describes deuterium-enriched cetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062307 - Aminopyrazine derivatives and compositions: The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090062306 - Novel pyrimidine compounds having benzyl (heterocyclic methyl) amine structure and medicament comprising the same: A compound represented by the following general formula (I), wherein R1, R2, R3, R4 and R5 represent hydrogen atom, a halogen atom, a lower alkyl group and the like, R6 represents an alkyl group, a cycloalkyl group and the like, R7 and R8 represent hydrogen atom, a lower alkyl group,... Agent: Greenblum & Bernstein, P.L.C

20090062308 - Methods of using sodium channel blockers: c

20090062309 - Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor: A pharmaceutical composition comprising an effective amount of at least one (a) an effective amount of at least one 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate derivative comprising pirazinoylguanidine, benzamil, dichlorobenzamil, 5-(N,N-dimethyl)-Amiloride, 5-(N-ethyl-N-isopropyl)-Amiloride, (N,N-hexamethylene)-Amiloride, 5-(N-methyl-N-isobutyl)-Amiloride, and Amiloride citrate; (b) an effective amount of a calcium increasing agent; and (c) a pharmaceutically acceptable excipient.... Agent: Harness, Dickey & Pierce, P.L.C

20090062310 - Deuterium-enriched voriconazole: The present application describes deuterium-enriched voriconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062311 - Macrocylic inhibitors of hepatitis c virus: e

20090062312 - Deuterium-enriched indiplon: The present application describes deuterium-enriched indiplon, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062313 - Pde5 inhibitor compositions and methods for treating cardiac indications: The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing a cardiac indication in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20090062314 - Purine derivatives as adenosine a1 receptor agonists and methods of use thereof: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090062315 - Pharmaceutical acceptable composition containing non-steroidal anti-inflammatory drug and local anesthetics: A pharmaceutical acceptable composition is provided. The composition comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), a local anesthetic, and an antiviral drug.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090062316 - Deuterium-enriched pelitrexol: The present application describes deuterium-enriched pelitrexol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062317 - Medicinal use of receptor ligands: Compounds of formula (I) are ligands of the melanin concentrating hormone-1 receptor (MCH-1R), useful in the treatment of diseases responsive to modulation of melanin concentrating hormone (MCH) activity, for example feeding disorders and diseases for which obesity is a risk factor (I): wherein ring B is selected from specific substituted... Agent: Banner & Witcoff, Ltd.

20090062318 - Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other... Agent: Gwen R. Acker Wood, Ph.d., J.d. Eckert Seamans Cherin & Mellott, LLC

20090062319 - Methods of inhibiting the interaction between s100 and the receptor for advanced glycation end-products: A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, or salt, hydrate, or solvate thereof. In some embodiments, the S100 protein is S100P. In some embodiments, the S100... Agent: Baker Botts, LLP

20090062320 - Method of treating disorders mediated by the fibroblast growth factor receptor: The disclosure includes a method of treating a warm-blooded animal having a disorder mediated by the fibroblast growth factor receptor (FGFR), in particular 8p11 myelo-proliferative syndrome (EMS), pituitary tumors, retinoblastoma, synovial sarcoma, chronic obstructive pulmonary disease (COPD), seborrheic keratosis, obesity, diabetes and related disorders, autosomal dominant hypophosphatemic Rickets (ADHR), X-chromosome... Agent: Novartis Institutes For Biomedical Research, Inc.

20090062321 - Hydroxybenzoate salts of metanicotine compounds: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds,... Agent: Pepper Hamilton LLP

20090062322 - Novel tricyclic spiropiperidines or spiropyrrolidines: t

20090062323 - Deuterium-enriched irinotecan: The present application describes deuterium-enriched irinotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062324 - Catecholamine derivatives and prodrugs thereof: The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.... Agent: Darby & Darby P.C.

20090062325 - Deuterium-enriched tiotropium: The present application describes deuterium-enriched tiotropium, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062326 - M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors: The present disclosure provides methods of treating a tumor using M3 muscarininc receptor antagonists, such as darifenacin. In some examples, the tumor expresses M3 muscarinic receptors, such as tumors associated with smoking. Also provided are compositions that can be used to practice such methods.... Agent: Klarquist Sparkman, LLP

20090062327 - Inhibitors of akt activity: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of... Agent: Merck And Co., Inc

20090062328 - Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods: Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the... Agent: Wolf Greenfield & Sacks, P.C.

20090062329 - Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity: The bisnaphthalimidopropyl derivatives with anti-parasitic and anti-cancer activity. Bisnaphthalimidopropyl derivatives (A) BNIPPut, BNIPDapen, BNIPDhex, BNIPDahep, BNIPDaoct, BNIPDanon, BNTPDadec, BNIPDadod, BNPDpta, BNIPDeta were synthesized in yields ranging from 50-70 and their cytotoxicity against colon cancer cells (CaCo-2) and the parasite Leishmania infantum determined using the MTT assay and by luciferase activity... Agent: Sughrue Mion, PLLC

20090062330 - Treatment of progressive neurodegenerative disease with ibudilast: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).... Agent: Foley And Lardner LLP Suite 500

20090062333 - 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists: wherein R2, R7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates... Agent: Theravance, Inc.

20090062335 - Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists: wherein R1, R2, R3, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and... Agent: Theravance, Inc.

20090062331 - Deuterium-enriched maraviroc: The present application describes deuterium-enriched maraviroc, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062332 - Disubstituted alkyl-8-azabicyclo[3.2.1] octane compounds as mu opioid receptor antagonists: where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for... Agent: Theravance, Inc.

20090062334 - Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists: wherein R1, R2, A, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and... Agent: Theravance, Inc.

20090062336 - Methods of diminishing co-abuse potential: Methods of diminishing or eliminating the co-abuse of a methylphenidate drug comprising identifying a patient or patient group suspected or likely to abuse said methylphenidate drug in combination with a substance known or suspected to give rise to l-ethylphenidate or psychotropic effect when ingested in the combination and making available... Agent: Woodcock Washburn LLP

20090062337 - Treatment of microbial infections: t

20090062339 - Compositions and methods for selective inhibition of nicotine acetylcholine receptors: The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090062338 - Nitroxides for use in treating or preventing cardiovascular disease: Pharmaceutical compositions are provided that are useful in treating cardiovascular disease. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to the cardiovascular disease. Methods are also provided for the use... Agent: Knobbe Martens Olson & Bear LLP

20090062340 - Novel biaromatic compounds which activate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof: a

20090062342 - Amines: The invention relates to novel amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of... Agent: Hoxie & Associates LLC

20090062341 - Nuclear receptor binding agents: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes... Agent: Pearl Cohen Zedek Latzer, LLP

20090062343 - Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Jones Day

20090062344 - Therapeutic substituted piperidone compounds: l

20090062345 - Amide derivatives as trpv1 antagonists:

20090062346 - Deuterium-enriched tipranavir: The present application describes deuterium-enriched tipranavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062347 - Deuterium-enriched axitinib: The present application describes deuterium-enriched axitinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062348 - Antifungal agent containing pyridine derivative: (wherein X represents an oxygen atom, a sulfur atom or —NH—, R1 represents a hydrogen atom, a halogen atom, a cyano group, an amino group or a substituent, and R2 and R3 independently represent a hydrogen atom, a halogen atom, a hydroxyl group or a substituent, except for a case... Agent: Birch Stewart Kolasch & Birch

20090062349 - 1-hydroxycycloalkanecarboxamide derivatives: α-Hydroxycycloalkanecarboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein formula (a) is a single or double bond; R1, R2 and R3 are each independently selected from H, halogen and OH; or R1 and R2 attached to the same carbon atom together represent oxo; R4 is H or... Agent: Merck And Co., Inc

20090062350 - Pesticidal composition: A pesticidal composition including a microcapsule in which an oil containing a pesticidal active ingredient and an organic solvent is covered with a wall made of a thermosetting resin; at least one kind selected from the group consisting of polyglycerin fatty acid ester, sucrose fatty acid ester and alkylbenzenesulfonic acid... Agent: Foley And Lardner LLP Suite 500

20090062351 - Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators: A compound of Formula (I): Formula (I) wherein: R1 is selected from hydrogen and C1-4alkyl; R2 is selected from: R4—C(R5aR5b)—, R4═C(R6)— and R7aC(R7b)═C(R6)—; R3X— is selected from methyl, methoxymethyl and; R4 is selected from (optionally substituted) C1-4alkyl, phenyl, C3-6cycloalkyl and heteroaryl; R5a and R5b are independently selected from hydrogen, fluoro... Agent: Morgan Lewis & Bockius LLP

20090062352 - Deuterium-enriched amlodipine: The present application describes deuterium-enriched amlodipine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062353 - Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20090062354 - Method of increasing the extent of absorption of tizanidine: An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090062355 - Pharmaceutical product:

20090062356 - Substituted benzimidazole derivatives:

20090062357 - Deuterium-enriched fluconazole: The present application describes deuterium-enriched fluconazole, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062358 - Peroxisome proliferator activated receptor alpha agonists: R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of... Agent: Eli Lilly & Company

20090062359 - Injectable capsaicin with non-local anesthetic sodium channel-blocker adjunctive agent: Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a non-anesthetic sodium channel blocker.... Agent: Davidson, Davidson & Kappel, LLC

20090062360 - Compounds which inhibit the glycine transporter and uses thereof: wherein R1 to R8 and n are defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further comprises processes to make these compounds and... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090062361 - Therapeutic hydantoins: e

20090062363 - Amide derivative or salt thereof: [Means for Resolution] It was found that an amide derivative characterized by the possession of a nitrogen-containing bicyclic hetero ring (e.g., an indole or the like), or a pharmaceutically acceptable salt thereof, has a strong antagonism for both of the 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of... Agent: Fitzpatrick Cella Harper & Scinto

20090062362 - Veterinary formulation for administration of a water-insoluble drug to a target animal through a water distribution system: This invention concerns a method for the preparation of a suspoemulsion formulation, which can be easily produced on an industrial scale and which allows the reproducible and effective administration of one or more water-insoluble veterinary drugs through water distribution systems. The water-insoluble veterinary drug, in finely ground form, is dispersed... Agent: Philip S. Johnson Johnson & Johnson

20090062364 - Deuterium-enriched celecoxib: The present application describes deuterium-enriched celecoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062365 - Pyrazoles for the treatment of gerd and ibs: The present invention relates to novel pyrazole derivatives having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux... Agent: White & Case LLP Patent Department

20090062366 - Pyrrolidine derivative or salt thereof: [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug... Agent: Sughrue Mion, PLLC

20090062367 - Deuterium-enriched eletriptan: The present application describes deuterium-enriched eletriptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062368 - Deuterium-enriched sunitinib: The present application describes deuterium-enriched sunitinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062370 - Method for increasing the speed of recovery and/or the speed of wound healing of injured animals: This invention is in the field of animal food, in particular food for wounded animals. Surprisingly, it has now been found that the speed of recovery of wounded animals may be increased by feeding the animal with a certain amount of natural occurring immune enhancing ingredients such as beta-glucans and/or... Agent: Nixon & Vanderhye, PC

20090062369 - Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels: Administration of sPLA2 inhibitors has been found to decrease sPLA2 levels in human serum. Provided herein are methods of decreasing serum sPLA2 levels in a subject in need thereof, as well as methods for accurately measuring sPLA2 levels in a serum sample.... Agent: Perkins Coie LLP

20090062371 - Oral preparation for promoting synthesis of tissue collagen: An object of the present invention is to provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which is safe and has an excellent effect. The present invention... Agent: Fitzpatrick Cella Harper & Scinto

20090062372 - Glycopyrronium salts and their therapeutic use: A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090062373 - Deuterium-enriched pf-184298: The present application describes deuterium-enriched PF-184298, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062374 - Deuterium-enriched lasofoxifene: The present application describes deuterium-enriched lasofoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062375 - Methods and compositions for the treatment of viral diseases: The invention provides a method of treating viral haemorrhagic fevers, such as that caused by Dengue virus, which comprises administering a composition comprising a pharmaceutically active amount of a matrix metalloproteinase inhibitor.... Agent: Bozicevic, Field & Francis LLP

20090062376 - Preparation of taxanes from 9-dihydro-13-acetylbaccatin iii: The present invention relates to a new process for the preparation of 9-dihydrobaccatin III intermediates as useful precursors for the preparation of paclitaxel, 1, docetaxel, 2, and analogues thereof. More particularly, the process comprises the steps of (i) concomitantly deacetylating esters at the 10-position and 13-position of 9-dihydro-13-acetylbaccatin III to... Agent: Buchanan, Ingersoll & Rooney PC

20090062377 - Anti-cancer combinations: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the... Agent: Foley & Lardner LLP

20090062378 - Nutraceutical mangosteen composition: Nutraceutical compositions derived from the fruit of the Garcinia mangostana L. or mangosteen plant and methods to make the same are provided. The nutraceutical mangosteen compositions employ novel combinations of mangosteen fruit pulp and pericarp, and can be additionally complemented by selected juice concentrates to yield a composition for improving... Agent: Mcandrews Held & Malloy, Ltd

20090062381 - Aqueous composition: In an aqueous composition comprising a 15-keto-prostaglandin compound as an active ingredient, a polyoxyethylene castor oil derivative is admixed. By admixing a polyoxyethylene castor oil derivative, the solubility of the 15-keto-PG compound in water is increased. In a preferable embodiment, the aqueous composition may further comprise a quaternary ammonium type... Agent: Sughrue Mion, PLLC

20090062379 - Compositions and methods for treating immune disorders: Green tea polyphenol compositions and methods of their use are provided. Certain aspects provide methods for modulating expression of one or more autoantigens using the disclosed green tea polyphenol compositions. Representative green tea polyphenols include, but are not limited to (−)-epigallocatechin-3-gallate. Other aspects provide methods for treating autoimmune disease.... Agent: Pabst Patent Group LLP

20090062380 - Isoflavones for treating mucopolysaccharidoses: The invention relates to the medical use of natural isoflavones and their semisynthetic derivatives or the pharmaceutically acceptable salts thereof for the therapeutic and/or prophylactic treatment of diseases, at the base of which lies an excessive production or storage of glycosaminoglycans, especially for treatment of mucopolysaccharidoses. The isoflavones and their... Agent: Matthias Scholl

20090062382 - External preparation for improving coital function: Use of a drug of the present invention enables to prevent or treat male penile erectile dysfunction and, at the same time, overcome a problem of female insertion impediment caused by increased resistance due to vaginal secretion disorder. Namely, a sexual life of patients (including aged persons) having coital dysfunction... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090062383 - Salts of substituted allophanates and their use in drugs: The present invention relates to salts of substituted allophanates, methods for their production, medicaments containing said compounds and the use of said compound for the production of medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20090062384 - Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease: e

20090062385 - Deuterium-enriched fesoterodine: The present application describes deuterium-enriched fesoterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062387 - Method of preventing nephrocalcinosis: The present invention provides the invention provides methods of reducing phosphate nephropathy in a mammal suffering from impairment of renal function, including administering to the mammal an amount of citrate that is effective to reduce serum phosphorous concentration.... Agent: Evan Law Group LLC

20090062386 - Simulants of toxants for training and testing: Compositions are formulated with generally regarded as safe (GRAS) ingredients for use as chemical simulants of toxants such as chemical warfare agents. The compositions can be used for training exercises, testing, and research studies and they can be applied safely to human skin. They include ultraviolet-excited fluorescent ingredients that make... Agent: Husch Blackwell Sanders LLP

20090062388 - Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain: The invention relates to the use of the acetyl L-carnitine, or a pharmaceutically acceptable salt thereof for the preparation of a medication for the preventive therapy for pain.... Agent: Nixon & Vanderhye, PC

20090062389 - In-shower lotion compositions comprising up to 10% free fatty acids wherein ratio of unsaturated to saturated fatty acids is at least 1:1: e

20090062390 - In-shower lotion compositions comprising up to 10% free fatty acids wherein ratio of unsaturated to saturated fatty acids is at least 1:1:

20090062392 - Deuterium-enriched gabapentin: The present application describes deuterium-enriched gabapentin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062393 - Deuterium-enriched pregabalin: The present application describes deuterium-enriched pregabalin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062391 - Use of a virucidal ointment in the nares for prevention of transmission and contraction of common colds: A novel method of preventing or inhibiting the contraction or communication of viruses which cause the common cold is proposed. Application of a virucidal ointment containing one or more organic acids (e.g. malic acid) with or without a surfactant (e.g. sodium C.sub.14-C.sub.16 olefin sulfonate) in a carrier agent (e.g. petrolatum)... Agent: Kent C. New

20090062394 - Transdermal delivery of ketoprofen polar derivatives: A topical or transdermal composition including a polar derivative of ketoprofen and a pharmaceutically acceptable topical or transdermal carrier, wherein the polar derivative of ketoprofen comprises a polarity that is greater than that of ketoprofen.... Agent: Foley And Lardner LLP Suite 500

20090062395 - Renin inhibitors for the treatment of hypertension: The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof as well as methods of preventing secondary complications linked to cessation of the... Agent: Novartis Corporate Intellectual Property

20090062396 - Novel haloalkoxy-substituted salicylic anilides: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.... Agent: High Point Pharmaceuticals, Inc.

20090062397 - Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins: The relatively low solubility of florfenicol (FEC) in water (1.3 mg/mL) limits its use in medicated drinking water systems for treatment of pulmonary disease of swine and poultry. Current formulations use a high volume organic solvent to reach the required FFC concentration of 13.5 mg/mL in an automated proportioner mixing... Agent: Intervet/schering-plough Animal Health Patent Department

20090062398 - Deuterium-enriched tolterodine: The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062399 - Deuterium-enriched sertraline: The present application describes deuterium-enriched sertraline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090062400 - Method of treating glaucoma using rasagiline: Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma.... Agent: Cooper & Dunham, LLP

20090062401 - Decaline-derived compounds as pharmaceutically active agents: The present invention relates to compounds having a decaline scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said decaline-derived compounds can be used for prophylaxsis and/or treatment of diabetes mellitus type I, diabetes... Agent: Amin, Turocy & Calvin, LLP

20090062402 - Active substance combination of licochalcone a and phenoxyethanol: A method for the prophylaxis or treatment of inflammatory skin conditions, which method comprises applying to the skin a cosmetic or pharmaceutical preparation comprising licochalcone A and phenoxyethanol. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention... Agent: Greenblum & Bernstein, P.L.C

20090062403 - Compositions and methods for treatment of disorders of protein aggregation: The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090062404 - Pharmaceutical composition: The present invention provides an intraoral rapid-disintegrating pharmaceutical composition which exhibits excellent intraoral disintegrating property and high hardness, and which can be applied, in particular, to a pharmaceutically active ingredient which is unstable in water. The pharmaceutical composition, which contains lactose and powdered cellulose, exhibits high hardness without prolongation of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090062405 - Cyclopropanecarboxaldehydes and their use in perfume compositions: e

20090062406 - Aqueous concentrates of isethionate, taurate and betaine:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.02766 seconds

PATENT INFO